Integra LifeSciences (IART) 10-Q 4 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 02, 2015
Document Documentand Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Trading Symbol	iart
Entity Registrant Name	INTEGRA LIFESCIENCES HOLDINGS CORP
Entity Central Index Key	917,520
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		36,982,277

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Total revenue, net	$ 226,367	$ 197,523	$ 641,574	$ 577,643
Costs and expenses:
Cost of goods sold	86,069	73,896	236,541	217,922
Research and development	13,938	11,134	37,029	33,549
Selling, general and administrative	113,424	93,788	306,007	283,057
Intangible asset amortization	2,942	1,598	6,418	4,839
Total costs and expenses	216,373	180,416	585,995	539,367
Operating income	9,994	17,107	55,579	38,276
Interest income	5	25	1	141
Interest expense	(6,464)	(5,912)	(17,404)	(16,436)
Other income (expense), net	1,827	(263)	2,984	203
Income from continuing operations before income taxes	5,362	10,957	41,160	22,184
Income tax expense	37,243	1,967	49,289	6,294
(Loss) income from continuing operations	(31,881)	8,990	(8,129)	15,890
Income (loss) from discontinued operations (net of tax expense, (benefit))	0	817	(10,370)	948
Net (loss) income	$ (31,881)	$ 9,807	$ (18,499)	$ 16,838
Basic net income (loss) per share:
Basic net income (loss) per common share from continuing operations (in dollars per share)	$ (0.90)	$ 0.28	$ (0.24)	$ 0.49
Basic net income (loss) per common share from discontinued operations (in dollars per share)	0	0.03	(0.31)	0.03
Basic net income (loss) per common share (in dollars per share)	(0.90)	0.31	(0.55)	0.52
Diluted net income per share:
Diluted net income (loss) per common share from continuing operations (in dollars per share)	(0.90)	0.27	(0.24)	0.48
Diluted net income (loss) per common share from discontinued operations (in dollars per share)	0	0.02	(0.31)	0.03
Diluted net income (loss) per common share (in dollars per share)	$ (0.90)	$ 0.29	$ (0.55)	$ 0.51
Weighted average common shares outstanding (See Note 11):
Basic (in shares)	35,279	32,450	33,682	32,374
Diluted (in shares)	35,279	32,906	33,682	32,844
Comprehensive income (loss) (See Note 12)	$ (33,315)	$ (7,181)	$ (26,364)	$ 645

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 79,311	$ 71,734
Trade accounts receivable, net of allowances of $5,876 and $5,659	125,465	110,414
Inventories, net	213,878	189,133
Deferred tax assets	46,897	30,564
Prepaid expenses and other current assets	39,361	27,691
Current assets of discontinued operations	0	99,785
Total current assets	504,912	529,321
Property, plant and equipment, net	197,200	193,626
Intangible assets, net	606,420	412,568
Goodwill	505,727	363,479
Deferred tax assets	4,955	4,471
Other assets	8,406	10,220
Non-current assets of discontinued operations	0	73,734
Total assets	1,827,620	1,587,419
Current liabilities:
Borrowings under senior credit facility	10,938	3,750
Accounts payable, trade	38,587	28,867
Deferred revenue	4,931	5,176
Accrued compensation	41,206	34,643
Accrued expenses and other current liabilities	44,285	39,809
Current liabilities of discontinued operations	0	13,780
Total current liabilities	139,947	126,025
Long-term borrowings under senior credit facility	502,188	413,125
Long-term convertible securities	216,604	213,121
Deferred tax liabilities	209,507	100,417
Other liabilities	29,274	27,778
Long-term liabilities of discontinued operations	0	(2,631)
Total liabilities	$ 1,097,520	$ 883,097
Commitments and contingencies
Stockholders’ equity:
Preferred stock; no par value; 15,000 authorized shares; none outstanding	$ 0	$ 0
Common stock; $0.01 par value; 60,000 authorized shares; 45,843 and 41,644 issued at September 30, 2015 and December 31, 2014, respectively	458	416
Additional paid-in capital	1,010,448	779,555
Treasury stock, at cost; 8,911 shares at September 30, 2015 and 8,903 shares at December 31, 2014	(367,121)	(367,121)
Accumulated other comprehensive loss	(41,723)	(23,488)
Retained earnings	128,038	314,960
Total stockholders’ equity	730,100	704,322
Total liabilities and stockholders’ equity	$ 1,827,620	$ 1,587,419

CONDENSED CONSOLIDATED BALANCE4

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Trade accounts receivable, allowances	$ 5,876	$ 5,659
Preferred Stock, par value (in dollars per share)	$ 0	$ 0
Preferred Stock, authorized shares (in shares)	15,000,000	15,000,000
Preferred Stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	60,000,000	60,000,000
Common stock, shares issued (in shares)	45,843,000	41,644,000
Treasury stock, shares (in shares)	8,911,000	8,903,000

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
OPERATING ACTIVITIES:
Net (loss) income	$ (18,499)	$ 16,838
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Loss (income) from discontinued operations, net of tax	10,370	(948)
Depreciation and amortization	40,596	34,042
Non-cash impairment charges	0	600
Deferred income tax	32,578	(89)
Amortization of debt issuance costs	1,645	2,060
Non-cash interest expense	5,874	5,256
Payment of accreted interest	(384)	0
Loss on disposal of property and equipment	124	505
Change in fair value of contingent consideration	359	(878)
Share-based compensation	11,788	11,234
Excess tax benefits from stock-based compensation arrangements	(3,678)	(1,207)
Changes in assets and liabilities, net of business acquisitions:
Accounts receivable	(9,206)	(12,409)
Inventories	(8,005)	(23,791)
Prepaid expenses and other current assets	7,423	11,566
Other non-current assets	1,224	(2,203)
Accounts payable, accrued expenses and other current liabilities	9,348	4,528
Deferred revenue	(185)	1,069
Other non-current liabilities	(72)	(5,229)
Net cash provided by operating activities of continuing operations	81,300	40,944
Net cash (used in) provided by operating activities of discontinued operations	(12,209)	17,762
Net cash provided by operating activities	69,091	58,706
INVESTING ACTIVITIES:
Purchases of property and equipment	(20,314)	(27,108)
Sale of property and equipment	1,438	0
Cash used in business acquisition, net of cash acquired	(308,256)	(235,000)
Net cash used in investing activities of continuing operations	(327,132)	(262,108)
Net cash used in investing activities of discontinued operations	(7,060)	(2,358)
Net cash used in investing activities	(334,192)	(264,466)
FINANCING ACTIVITIES:
Borrowings under senior credit facility	545,000	385,000
Repayments under senior credit facility	(448,750)	(160,000)
Repayment of 2016 convertible notes	(2,519)	0
Distribution to SeaSpine	(47,013)	0
Payment of debt issuance costs	(1,050)	(3,110)
Proceeds from the issuance of common stock, net of issuance costs	219,888	0
Principal payments under capital lease obligations	(553)	(370)
Proceeds from exercised stock options	7,345	8,317
Excess tax benefits from stock-based compensation arrangements	3,677	1,207
Net cash provided by financing activities	276,025	231,044
Effect of exchange rate changes on cash and cash equivalents	(3,347)	(5,667)
Net increase in cash and cash equivalents	7,577	19,617
Cash and cash equivalents at beginning of period	71,734	120,614
Cash and cash equivalents at end of period	$ 79,311	$ 140,231

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION General The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise. In the opinion of management, the September 30, 2015 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations and cash flows of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K. The December 31, 2014 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States. Operating results for the three- and nine-month periods ended September 30, 2015 are not necessarily indicative of the results to be expected for the entire year. On July 1, 2015, the Company completed the distribution of 100% of the outstanding common shares of SeaSpine Holdings Corporation ("SeaSpine") to Integra shareholders who received one share of SeaSpine common stock for every three shares of Integra common stock held as of the close of business on the record date, June 19, 2015. The Company has classified the results of operations, cash flows, and related assets and liabilities of SeaSpine as discontinued operations for all periods presented in the Company's Form 10-Q. Unless indicated otherwise, the information in the Notes to the condensed consolidated financial statements relates to the Company's continuing operations. Refer to Note 2 - Discontinued Operations , for additional information regarding the distribution. The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including in-process research and development, amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of pension assets and liabilities, valuation of derivative instruments, valuation of the equity component of convertible debt instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates. Certain amounts from the prior year’s financial statements have been reclassified in order to conform to the current year’s presentation. Recently Issued Accounting Standards In April 2014, the FASB issued amendments to guidance for reporting discontinued operations and disposals of components of an entity. The amended guidance requires that a disposal representing a strategic shift that has (or will have) a major effect on an entity’s financial results or a business activity classified as held for sale should be reported as discontinued operations. The amendments also expand the disclosure requirements for discontinued operations and add new disclosures for individually significant dispositions that do not qualify as discontinued operations. The amendments are effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2014 (early adoption is permitted only for disposals that have not been previously reported). The new guidance is effective for Integra prospectively for all disposals (or classifications as held for sale) of components of an entity that occur after January 1, 2015. The spin-off of the spine business by the Company on July 1, 2015 met the definition of a discontinued operation under the new guidance and, as a result, the Company reflected the provisions of the new guidance in its third quarter 2015 results. In May 2014, the FASB issued Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) . The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should 1) identify the contract(s) with a customer, 2) identify the performance obligations in the contract, 3) determine the transaction price, 4) allocate the transaction price to the performance obligations in the contract, and 5) recognize revenue when (or as) the entity satisfies a performance obligation. In July 2015, the FASB deferred for one year the effective date of the new revenue standard, but early adoption will be permitted. The new standard will be effective for the Company on January 1, 2018. The Company is in the process of evaluating the impact of this standard on its financial statements. In June 2014, the FASB issued Update No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (Topic 718). The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718 as it relates to awards with performance conditions that affect vesting to account for such awards. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. This update is effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period, and early adoption is permitted. The implementation of the amended guidance is not expected to have a material impact on the consolidated financial position or results of operations. In August 2014, the FASB issued Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern . The amendment requires management to evaluate, for each annual and interim reporting period, whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date the financial statements are issued or are available to be issued. If substantial doubt is raised, additional disclosures around management’s plan to alleviate these doubts are required. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2016. The implementation of the amended guidance is not expected to have an impact on current disclosures in the financial statements. In April 2015, the FASB issued Update No. 2015-03, Simplifying the Presentation of Debt Issuance Costs . The amendment requires that all costs incurred to issue debt be presented in the balance sheet as a direct deduction from the carrying value of the debt. The new standard is limited to the presentation of debt issuance costs and does not affect the recognition or measurement of debt issuance costs. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2015. The implementation of the amended guidance is not expected to have a material impact on the consolidated results of operations and will result in a reclassification of the debt issuance costs from other long-term assets to long-term debt when adopted. In August 2015, the FASB issued Update No. 2015-15, Interest - Imputation of Interest . The amendment requires entities to present debt issuance costs related to a recognized debt liability as a direct deduction from the carrying amount of that debt liability. The guidance in ASU No. 2015-03 does not address presentation or subsequent measurement of debt issuance costs related to line-of-credit arrangements. Given the absence of authoritative guidance within ASU No. 2015-03 for debt issuance costs related to line-of-credit arrangements, the SEC staff would not object to an entity's deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2015. The implementation of the amended guidance is not expected to have a material impact on the consolidated financial position or results of operations. In September 2015, the FASB issued Update No. 2015-16, Simplifying the Accounting for Measurement-Period Adjustments . The amendment requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. This update also requires an entity to present separately in the income statement or disclose in the notes, the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2015. The new standard must be applied prospectively to adjustments to provisional amounts that occur after the effective date. Early application is permitted for financial statements that have not been issued. The implementation of the amended guidance is not expected to have a material impact on the consolidated results of operations or disclosures in the financial statements. There are no other recently issued accounting standards that are expected to have a material effect on the financial position, results of operations or cash flows.

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS	9 Months Ended
	Sep. 30, 2015
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS	DISCONTINUED OPERATIONS On October 29, 2014, Integra's Board of Directors approved the announcement of a plan to separate SeaSpine from Integra as a new, publicly traded medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. Integra's board of directors based this determination, in part, on its belief that the tax-free distribution of SeaSpine shares to Integra stockholders is the most efficient manner to separate our business from Integra's other medical technology businesses. On November 3, 2014, the Company announced its intention to separate its spine business, which was previously a separate reportable segment. On July 1, 2015, the Company completed the distribution of 100% of the outstanding common stock of SeaSpine to Integra stockholders, who received one share of SeaSpine common stock for every three shares of Integra common stock held as of the close of business on the record date, June 19, 2015. The Company and SeaSpine share three board members, including the chair of Integra’s board of directors who is lead director for SeaSpine. The separation agreement ensures that SeaSpine had approximately $47.0 million of total cash immediately following the distribution. No (gain) or loss was recognized on the part of the Company or shareholders as a result of the distribution resulting from the separation of the spine business. The historical results of operations, cash flows, and statement of financial position of SeaSpine have been presented as discontinued operations in the condensed consolidated financial statements and prior periods have been restated. Discontinued operations include results of SeaSpine's business except for certain allocated corporate overhead costs and certain costs associated with transition services provided by Integra to SeaSpine. These allocated costs will remain part of continuing operations. Discontinued operations also include other costs incurred by Integra to separate SeaSpine from Q4 2014 through Q2 2015. These costs include transaction charges, advisory and consulting fees, and information system expenses. For Q3 2015 and going forward, SeaSpine is a stand-alone public company that will separately report its financial results. Due to differences between the basis of presentation for discontinued operations and the basis of presentation as a stand-alone company, the financial results of SeaSpine included within discontinued operations for the Company may not be indicative of actual financial results of SeaSpine as a stand-alone company. The following table summarizes results from discontinued operations of SeaSpine included in the condensed consolidated statement of operations: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 (in thousands) (in thousands) Total revenue $ — $ 33,606 $ 65,775 $ 102,658 Costs and expenses — 32,986 80,618 102,077 Operating income (loss) — 620 (14,843 ) 581 Other income (expense), net — (34 ) (766 ) (61 ) Income (loss) from discontinued operations before tax — 586 (15,609 ) 520 Provision (benefit) for income taxes — (231 ) (5,239 ) (428 ) Net income (loss) from discontinued operations $ — $ 817 $ (10,370 ) $ 948 No income or expense has been recorded for the SeaSpine business after the separation from Integra on July 1, 2015. The following table presents Integra's spine business assets and liabilities presented as discontinued operations as of December 31, 2014: December 31, 2014 (in thousands) Assets: Cash $ 260 Accounts receivable 21,504 Inventory 47,981 Other current assets 30,040 Current assets of discontinued operations 99,785 Property, plant, and equipment, net 16,360 Intangible assets, net 46,891 Other assets 10,483 Non-current assets of discontinued operations 73,734 Total assets of discontinued operations $ 173,519 Liabilities: Accounts payable $ 5,193 Accrued compensation 6,300 Accrued expenses and other current liabilities 2,287 Current liabilities of discontinued operations 13,780 Other liabilities 2,631 Long-term liabilities of discontinued operations 2,631 Total liabilities of discontinued operations $ 16,411 The following table presents Integra's spine business assets and liabilities removed from the condensed consolidated balance sheet as of July 1, 2015: July 1, 2015 (in thousands) Assets: Cash $ 46,848 Accounts receivable 21,273 Inventory 49,380 Other current assets 16,262 Current assets of discontinued operations 133,763 Property, plant, and equipment, net 21,079 Intangible assets, net 42,837 Other assets 4,449 Non-current assets of discontinued operations 68,365 Total assets of discontinued operations $ 202,128 Liabilities: Accounts payable $ 7,065 Accrued compensation 5,960 Accrued expenses and other current liabilities 3,350 Current liabilities of discontinued operations 16,375 Deferred tax liabilities 13,329 Other liabilities 2,500 Long-term liabilities of discontinued operations 15,829 Total liabilities of discontinued operations $ 32,204 The removal of SeaSpine's net assets and unrealized accelerated currency translation adjustment is presented as a reduction in Integra's retained earnings. In order to effect the separation and govern Integra's relationship with SeaSpine after the separation, the Company entered into a Separation and Distribution Agreement and other agreements including a Tax Matters Agreement, an Employee Matters Agreement, several supply agreements, and a Transition Services Agreement. The Separation and Distribution Agreement governs the separation of the spine business, the transfer of assets and other matters related to the Company's relationship with SeaSpine. The Tax Matters Agreement governs the respective rights, responsibilities and obligations of SeaSpine and Integra with respect to taxes, tax attributes, tax returns, tax proceedings and certain other tax matters. The Employee Matters Agreement governs the compensation and employee benefit obligations with respect to the current and former employees and non-employee directors of SeaSpine and Integra, and generally allocates liabilities and responsibilities relating to employee compensation, benefit plans and programs. The Employee Matters Agreement provides that employees of SeaSpine will no longer participate in benefit plans sponsored or maintained by Integra. In addition, the Employee Matters Agreement provides that each of the parties will be responsible for their respective former and current employees and compensation plans for such current employees. The Company entered into several Supply Agreements in which SeaSpine engaged Integra to be the product supplier of Integra's former Integra Mozaik TM product line ("Mozaik") for a three - year period following the separation after which there will be no defined terms and this will be considered a normal purchase/sale arrangement. This product line has been licensed to SeaSpine in conjunction with the spin-off. Prior to the spin-off, the sale of Mozaik products from an Integra facility to a SeaSpine facility eliminated in Integra's historical consolidated financial results of operations. The revenue and cost of goods sold related to prior sales of Mozaik to SeaSpine have been restated and are presented in Integra's continuing operations results of operations. The Company has recorded $1.9 million and $1.4 million in revenue related to the sale of Mozaik products for the three months ended September 30, 2015 and 2014 , respectively and $1.1 million and $0.6 million in cost of goods sold for the three months ended September 30, 2015 and 2014 , respectively, in its continuing operations. Additionally, the Company has recorded $7.5 million and $4.2 million in revenue for the nine months ended September 30, 2015 and 2014 and $2.4 million and $1.9 million in cost of goods sold for the nine months ended September 30, 2015 and 2014 , respectively, in its continuing operations. Under the terms of the Transition Services Agreement, the Company agreed to provide administrative, site services, information technology systems and various other corporate and support services to SeaSpine over various periods after the separation on a cost or cost-plus basis. The most significant components of the service income is the provision of IT and legal services which the Company anticipates will be largely completed by the end of the first quarter of 2016. In the three and nine months ended September 30, 2015 other income (expense), net includes $1.8 million of income in respect of the provision of services to SeaSpine.

BUSINESS ACQUISITIONS

BUSINESS ACQUISITIONS	9 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
BUSINESS ACQUISITIONS	BUSINESS ACQUISITIONS TEI On July 17, 2015, the Company executed the two merger agreements (collectively, the "Agreements") under which the Company acquired TEI Biosciences, Inc., a Delaware corporation ("TEI Bio"), and TEI Medical Inc., a Delaware corporation ("TEI Med", collectively "TEI") for an aggregate purchase price of approximately $312.4 million ( $210.4 million for TEI Bio and $102.0 million for TEI Med) subject in each case to purchase price adjustments for certain working capital changes. The purchase price consists of a cash payment to the former shareholders of TEI Bio and TEI Med of approximately $312.4 million upon the closing of the transaction, net of $1.2 million of acquired cash. TEI Bio is in the business of developing and commercializing biologic devices for soft tissue repair and regenerative applications, including dura and hernia repair and plastic and reconstructive surgery. TEI Med holds a license to TEI Bio’s regenerative technology in the fields of wound healing and orthopedics. The Company recorded revenue for TEI of approximately $13.2 million in the condensed consolidated statements of operations for the three- and nine-month period ended September 30, 2015 . The net income or loss attributable to this acquisition cannot be identified on a stand-alone basis because it is in the process of being integrated into the Company's operations. The following summarizes the preliminary allocation of the purchase price as of September 30, 2015 based on the fair value of the assets acquired and liabilities assumed: Preliminary Purchase Price Allocation (Dollars in thousands) Cash $ 1,241 Accounts receivable, net 9,011 Inventory 23,223 Income tax receivable 5,135 Other current assets 2,270 Property, plant, and equipment 2,027 Intangible assets: Wtd. Avg. Life: Developed Technology 167,400 14 -16 Contractual Relationships 51,345 11 -14 Leasehold Interest 69 Goodwill 148,935 Total assets acquired 410,656 Accrued expenses and other liabilities 9,732 Deferred tax liabilities 88,565 Net assets acquired $ 312,359 Metasurg On December 5, 2014, the Company acquired certain assets of Koby Ventures II, L.P. dba Metasurg ("Metasurg") for an aggregate purchase price of $27.6 million (including working capital and purchase price adjustments of $0.4 million ). The purchase price consists of an initial cash payment to Metasurg of $26.5 million , a separate purchase price adjustment cash payment of $0.4 million , and contingent consideration with an acquisition date fair value of $0.7 million . The potential maximum undiscounted contingent consideration of $38.5 million is based on reaching certain sales levels for acquired products from April 1, 2015 through June 30, 2016. The fair value of this liability is based on future sales projections of the Metasurg product under various potential scenarios and weighting the probability of these outcomes for the twelve-month period ended December 31, 2015. At the date of the acquisition, the cash flow projection was discounted using an internal rate of return of 19.9% . These fair value measurements were based on significant inputs not observed in the market and thus represented a Level 3 measurement. Metasurg develops intuitive implant systems for the foot and ankle market and sells almost entirely in the U.S. market. The acquired foot and ankle products will enhance the Company's lower extremities market position. The Company recorded revenue for Metasurg of approximately $1.8 million and $5.1 million in the condensed consolidated statements of operations for the three- and nine-month period ended September 30, 2015 . The net income or loss attributable to this acquisition cannot be identified on a stand-alone basis because it has been fully integrated into the Company's operations. The Company adjusted the preliminary purchase price allocation during the quarter ended June 30, 2015 to reflect the $0.4 million working capital and purchase price adjustment. The following summarizes the final allocation of the purchase price as of September 30, 2015 based on the fair value of the assets acquired and liabilities assumed: Final Purchase Price Allocation (Dollars in thousands) Inventory $ 4,800 Property, plant, and equipment 1,246 Intangible assets: Wtd. Avg. Life: Technology product rights 20,590 8 - 14 Years In-process research and development 190 Indefinite Goodwill 732 Net assets acquired $ 27,558 MicroFrance On October 27, 2014, the Company acquired all outstanding shares of Medtronic Xomed Instrumentation, SAS ("MicroFrance") from Medtronic, Inc. ("Medtronic") as well as certain assets of Medtronic for $60.1 million in cash (including working capital and purchase price adjustments of $1.5 million , of which $0.8 million was recorded against goodwill). MicroFrance specializes in manual ear, nose, and throat ("ENT") surgical instruments and designs, manufactures, and sells reusable handheld instruments to ENT and laparoscopy surgical specialists around the world. The acquired ENT instruments fill a portfolio gap for the Company with clear growth opportunities through market adjacencies and provides for increased scale and reach in the international market. The Company recorded revenue for MicroFrance of approximately $6.7 million and $18.8 million in the condensed consolidated statements of operations for the three- and nine-month period ended September 30, 2015 . The net income or loss attributable to this acquisition cannot be identified on a stand-alone basis because it has been fully integrated into the Company's operations. The Company adjusted the preliminary purchase price allocation during the quarter ended March 31, 2015 to reflect the $1.5 million working capital and purchase price adjustments. The following summarizes the final allocation of the purchase price as of September 30, 2015 based on the fair value of the assets acquired and liabilities assumed: Final Purchase Price Allocation (Dollars in thousands) Cash $ 2,195 Inventory 3,155 Prepaid expenses 620 Property, plant, and equipment 3,675 Other current assets 5,025 Intangible assets: Wtd. Avg. Life: Trade name 11,990 20 Years Technology 4,580 15 - 16 Years Customer relationships 18,130 12 - 16 Years Goodwill 16,607 Total assets acquired 65,977 Accounts payable and other liabilities 5,910 Net assets acquired $ 60,067 Confluent Surgical, Inc. On January 15, 2014, the Company acquired all outstanding shares of Confluent Surgical, Inc., ("Confluent Surgical") - including its surgical sealant and adhesion barrier product lines - from Covidien Group S.a.r.l, ("Covidien") for an aggregate purchase price of $255.9 million . The purchase price consists of an initial cash payment to Covidien of $231.0 million upon the closing of the transaction, a separate prepayment of $4.0 million made under a transitional supply agreement with an affiliate of Covidien, and contingent consideration with an acquisition date fair value of $20.9 million . The potential maximum undiscounted contingent consideration of $30.0 million consists of $25.0 million upon obtaining certain U.S. governmental approvals and $5.0 million upon obtaining certain European governmental approvals, both related to the completion of the transition of the Confluent Surgical business to the Company. The transitional supply agreement secures the supply of the acquired products from an affiliate of Covidien until the earlier of (i) the time that the transition of the Confluent Surgical business as discussed above is complete, or (ii) the fifth anniversary of the effective date of the agreement (the agreement also contains an option to extend for another two years by providing written notice at least 180 days prior to the end of the initial five -year period). This agreement contains financial incentives to the affiliate of Covidien for the timely supply of products each fiscal quarter through the third anniversary of the agreement. The prices paid under the supply agreement are essentially flat through the third anniversary of the agreement, and then increase significantly each of the following three years. The Company also entered into a transition services agreement with an affiliate of Covidien at the closing for services such as customer service, accounting and information technology management, clinical and regulatory affairs, manufacturing transition services, and other functions. This acquisition complements the Company's global neurosurgery growth strategy aimed at providing a broader set of solutions for surgical procedures in the head. The Company recorded revenue for Confluent Surgical of approximately $20.6 million and $57.2 million in the condensed consolidated statements of operations for the three- and nine-month periods ended September 30, 2015 and $17.7 million and $50.1 million for the three- and nine-month periods ended September 30, 2014 . The net income or loss attributable to this acquisition cannot be identified on a stand-alone basis because it has been fully integrated into the Company's operations. The Company adjusted the preliminary purchase price allocation during the quarter ended June 30, 2014 to reduce deferred tax liabilities by $12.4 million . This adjustment offset goodwill and was the result of the Company analyzing and revising its tax positions in certain jurisdictions. The following summarizes the final allocation of the purchase price as of September 30, 2015 based on the fair value of the assets acquired and liabilities assumed: Final Purchase Price Allocation (Dollars in thousands) Inventory deposit $ 4,000 Fixed assets 438 Intangible assets: Wtd. Avg. Life Technology product rights 239,800 3 - 20 Years Other 400 Less than 1 year Deferred tax assets - long term 12 Goodwill 105,331 Total assets acquired 349,981 Contingent supply liability 5,891 Other 731 Deferred tax liabilities - long term 87,464 Net assets acquired $ 255,895 Subsequent to the acquisition date, a regulatory event occurred that resulted in the full-impairment of one of the acquired technology product rights of $0.6 million . This event was not known, or knowable, at the time of the acquisition and therefore the impairment has been included in the Company's cost of sales. The Company accounted for the contingent supply liability by recording its fair value as a liability on the date of the acquisition based on a discounted cash-flow model. This contingent supply liability relates to contractual quarterly incentive payments that will be made to an affiliate of Covidien if certain supply minimums under the transitional supply agreement are met. The Company accounted for the contingent consideration by recording its fair value as a liability on the date of the acquisition. The contingent consideration relates to the Company's obtaining certain U.S. and European regulatory approvals. At the date of the acquisition, both of these milestones were valued using a discount rate of 2.2% , which is equivalent to the cost of debt for the estimated time horizon, and an overall probability of occurring of 95% . Accordingly, on January 15, 2014 the Company recorded a $20.9 million liability representing the initial fair value estimate of the probability weighted contingent consideration that management believes will be paid between early 2017 and late 2018. Depending on the expected timing of the estimated payments, the acquisition date fair value of the probability adjusted payments could have been $0.3 million higher or $0.4 million lower. These fair value measurements were based on significant inputs not observed in the market and thus represented a Level 3 measurement. The contingent consideration is re-measured to fair value at each reporting date until the contingency is resolved, and those changes in fair value are recognized in earnings. The goodwill recorded in connection with these acquisitions is based on (i) expected cost savings, operating synergies and other benefits expected to result from the combined operations, (ii) the value of the going-concern element of the existing businesses (that is, the higher rate of return on the assembled net assets versus if the Company had acquired all of the net assets separately), and (iii) intangible assets that do not qualify for separate recognition such as an assembled workforce. The acquisitions generated a combination of deductible and non-deductible goodwill. Contingent Consideration The Company increased the fair value of contingent consideration during the nine -month period ended September 30, 2015 to reflect the change in the time value of money during the period. A reconciliation of the opening balances to the closing balances of these Level 3 measurements is as follows (in thousands): Location in Statement of Operations Balance as of January 1, 2015 $ 22,008 Loss from increase in fair value of contingent consideration liabilities 359 Selling, general and administrative Fair value at September 30, 2015 $ 22,367 The entire contingent consideration balance was included in Other liabilities at September 30, 2015 and December 31, 2014 . Pro Forma Results The following unaudited pro forma financial information summarizes the results of operations for the three and nine months ended September 30, 2015 and 2014 as if the acquisitions completed by the Company during 2015 and 2014 had been completed as of the beginning of the prior year. The pro forma results are based upon certain assumptions and estimates, and they give effect to actual operating results prior to the acquisition and adjustments to reflect (i) the change in interest expense, depreciation expense, and intangible asset amortization, (ii) certain external expenses related to the acquisition as if they were incurred on January 1 of the year prior to the acquisition that will not be recurring in the post-acquisition periods, and (iii) income taxes on the aforementioned adjustments at the Company’s statutory rate. No effect has been given to other cost reductions or operating synergies. As a result, these pro forma results do not necessarily represent results that would have occurred if the acquisition had taken place on the basis assumed above, nor are they indicative of the results of future combined operations. Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 (In thousands, except per share amounts) (In thousands, except per share amounts) Total revenue $ 229,402 $ 223,837 $ 677,740 $ 656,584 Net (loss) income $ (31,697 ) $ 10,160 $ (5,930 ) $ 20,251 Net (loss) income per share: Basic $ (0.90 ) $ 0.31 $ (0.18 ) $ 0.63

INVENTORIES

INVENTORIES	9 Months Ended
	Sep. 30, 2015
Inventory, Net [Abstract]
INVENTORIES	INVENTORIES Inventories, net consisted of the following: September 30, 2015 December 31, 2014 (In thousands) Finished goods $ 130,626 $ 120,477 Work in process 46,861 38,938 Raw materials 36,391 29,718 $ 213,878 $ 189,133

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	GOODWILL AND OTHER INTANGIBLE ASSETS In the first quarter of 2015 the Company revised its reportable segments in connection with the realignment of its portfolio. Specifically, the Company integrated the five existing business divisions into three global divisions, no longer focusing on international as a separate reportable segment but managing each business globally. The change in reportable segments resulted in the Company's requirement to reallocate existing goodwill to the new reportable segments based on the relative fair value of the Company's four underlying reporting units. With the reportable segments now being managed at a global level, goodwill previously assigned to the EMEA, LAPAC, and Private Label reporting units was reallocated to the new global reporting units. On July 1, 2015, the Company completed the separation of its spine business, which also represented a global reporting unit. See Note 2 - Discontinued Operations for additional information. Following the separation, the Company has three remaining underlying reporting units. The Company estimated the fair value of the reporting units using a discounted cash flow model, which incorporates significant estimates and assumptions made by management which, by their nature, are characterized by uncertainty. Inputs used to fair value the Company's reporting units are considered inputs of the fair value hierarchy. For Level 3 measurements, significant increases or decreases in long-term growth rates or discount rates in isolation or in combination could result in a significantly lower or higher fair value measurement. The key assumptions impacting the valuation included the following: • The reporting unit's financial projections, which are based on management's assessment of regional and macroeconomic variables, industry trends and market opportunities, and the Company's strategic objectives and future growth plans. • The projected terminal value for the reporting unit, which represents the present value of projected cash flows beyond the last period in the discounted cash flow analysis. The terminal value reflects the Company's assumptions related to long-term growth rates and profitability, which are based on several factors, including local and macroeconomic variables, market opportunities, and future growth plans. • The discount rate used to measure the present value of the projected future cash flows is set using a weighted-average cost of capital method that considers market and industry data as well as the Company's specific risk factors that are likely to be considered by a market participant. The weighted-average cost of capital is the Company's estimate of the overall after-tax rate of return required by equity and debt holders of a business enterprise. Based on the Company's fair value calculations given the excess of the Specialty Surgical Solutions Instruments, Specialty Surgical Solutions Neurosurgery, and Orthopedics and Tissue Technologies estimated fair value over their carrying value after the reallocation of goodwill, management concluded that any future goodwill impairment is not likely. Refer to Note 13 - Segment and Geographic Information for more information on the change in reportable segments. Changes in the carrying amount of goodwill for the nine months ended September 30, 2015 were as follows: Specialty Surgical Solutions Orthopedics and Tissue Technologies Total (In thousands) Goodwill at December 31, 2014 $ 281,829 $ 81,650 $ 363,479 MicroFrance working capital and purchase price adjustments (1,069 ) — (1,069 ) Metasurg working capital and purchase price adjustment — 263 263 TEI Acquisition — 148,935 148,935 Foreign currency translation (4,363 ) (1,518 ) (5,881 ) Balance, September 30, 2015 $ 276,397 $ 229,330 $ 505,727 The components of the Company’s identifiable intangible assets were as follows: September 30, 2015 Weighted Average Life Cost Accumulated Amortization Net (Dollars in thousands) Completed technology 17 years $ 480,991 $ (61,030 ) $ 419,961 Customer relationships 12 years 153,344 (66,729 ) 86,615 Trademarks/brand names (2) 30 years 91,288 (15,830 ) 75,458 Supplier relationships 27 years 34,721 (11,879 ) 22,842 All other (1) 4 years 2,721 (1,177 ) 1,544 $ 763,065 $ (156,645 ) $ 606,420 December 31, 2014 Weighted Average Life Cost Accumulated Amortization Net (Dollars in thousands) Completed technology 18 years $ 314,664 $ (46,339 ) $ 268,325 Customer relationships 13 years 105,201 (63,689 ) 41,512 Trademarks/brand names 34 years 44,220 (15,455 ) 28,765 Trademarks/brand names (2) Indefinite 48,484 — 48,484 Supplier relationships 27 years 34,721 (10,809 ) 23,912 All other (1) 4 years 2,910 (1,340 ) 1,570 $ 550,200 $ (137,632 ) $ 412,568 (1) At September 30, 2015 and December 31, 2014 , all other included in-process research and development ("IPR&D") of $1.4 million in both periods, which was indefinite-lived. (2) In August 2015, the Company reevaluated the Miltex, CUSA, Luxtec, and Omni-Tract trade names and determined that they are no longer indefinite-lived intangible assets. The Company assigned remaining useful lives ranging from 20 to 30 years , consistent with other trademarks/brand names, and began amortization. During the nine months ended September 30, 2014 , the Company recorded an impairment charge of $0.6 million in cost of goods sold related to technology assets acquired from Confluent Surgical that will no longer be sold resulting from a regulatory event that occurred after the acquisition date. Based on quarter-end exchange rates, annual amortization expense (including amounts reported in cost of product revenues, but excluding any possible future amortization associated with acquired in-process research and development) is expected to approximate $36.0 million in 2015, $40.5 million in 2016, $39.7 million in 2017, $39.6 million in 2018 and $39.5 million in 2019. Identifiable intangible assets are initially recorded at fair market value at the time of acquisition using an income or cost approach.

DEBT

DEBT	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
DEBT	DEBT Amended and Restated Senior Credit Agreement On August 28, 2015 , the Company entered into a second amendment (the “Second Amendment”) to that certain Third Amended and Restated Credit Agreement, dated as of July 2, 2014 (as amended by that certain First Amendment to Third Amended and Restated Credit Agreement, dated as of December 19, 2014, and as further amended by the Second Amendment, the “Credit Agreement”) among the Company, a syndicate of lending banks, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, Wells Fargo Bank, National Association, as Syndication Agent, and HSBC Bank USA, National Association, Royal Bank of Canada, Citizens Bank, National Association, DNB Capital LLC, Crédit Agricole-Corporate and Investment Bank, and TD Bank, N.A., as Co-Documentation Agents. The Company's Senior Credit Facility was originally amended and restated on August 10, 2010, and that agreement was then amended on June 8, 2011, May 11, 2012, June 21, 2013, and July 2, 2014 as previously disclosed. The Second Amendment creates an aggregate principal amount of up to $1.1 billion available to the Company through the following facilities: i. a $750.0 million revolving credit facility, which includes a $60.0 million sublimit for the issuance of standby letters of credit and a $60.0 million sublimit for swingline loans, and ii. a $350.0 million term loan facility. In connection with the Second Amendment, the Company borrowed $200.0 million of incremental term loans as permitted under the original terms of the Senior Credit Facility. Additionally, the Second Amendment (i) enables the Company to incur up to $200.0 million of incremental loans in the future and (ii) modifies the consolidated leverage ratio covenant in the Credit Agreement. The Senior Credit Facility allows the Company to further increase the size of either the revolving credit facility or the term loan facility, or a combination thereof, by an aggregate of $200.0 million with additional commitments. The July 2014 amended and restated Senior Credit Facility extended the maturity date of the prior facility from June 8, 2016 to July 2, 2019. On December 19, 2014, the Company entered into a first amendment to the Senior Credit Facility which modified covenants to permit the distribution and/or dividend by the Company of its spine business to the Company's public stockholders. The intent of the amendment was to permit the Company to consummate the spine business spin-off transaction. Borrowings under the Senior Credit Facility bear interest, at the Company’s option, at a rate equal to: i. the Eurodollar Rate (as defined in the amendment and restatement) in effect from time to time plus the applicable rate (ranging from 1.00% to 1.75% ), or ii. the highest of: 1. the weighted average overnight Federal funds rate, as published by the Federal Reserve Bank of New York, plus 0.50% , 2. the prime lending rate of Bank of America, N.A., or 3. the one-month Eurodollar Rate plus 1.00% . The applicable rates are based on the Company’s consolidated total leverage ratio (defined as the ratio of (a) consolidated funded indebtedness less cash in excess of $40.0 million that is not subject to any restriction of the use or investment thereof to (b) consolidated EBITDA) at the time of the applicable borrowing. The Company will also pay an annual commitment fee (ranging from 0.15% to 0.30% , based on the Company’s consolidated total leverage ratio) on the daily amount by which the revolving credit facility exceeds the outstanding loans and letters of credit under the credit facility. The Senior Credit Facility is collateralized by substantially all of the assets of the Company’s U.S. subsidiaries, excluding intangible assets. The Senior Credit Facility is subject to various financial and negative covenants and at September 30, 2015 the Company was in compliance with all such covenants. In connection with the modification of the 2014 amendment and restatement of the Senior Credit Facility, the Company capitalized $3.2 million of incremental financing costs, and expensed $0.3 million of previously capitalized financing costs. On July 2, 2014, the Company borrowed $422.0 million under the Senior Credit Facility consisting of a $150.0 million term loan and $272.0 million under its revolving credit facility. The Company used the funds to repay the balance of its previous Senior Credit Facility. The outstanding borrowings have one, two, three, six months, or, if available, twelve months interest periods. At September 30, 2015 and December 31, 2014 , there was $165.0 million and $266.9 million outstanding under the revolving credit component of the Senior Credit Facility at a weighted average interest rate of 1.7% and 1.7% , respectively. At September 30, 2015 , there was approximately $586.9 million available for borrowing under the Senior Credit Facility. The Company considers the balance to be long-term in nature based on its current intent and ability to repay the borrowing outside of the next twelve-month period. At September 30, 2015 there was $348.1 million outstanding under the term loan component of the Senior Credit Facility at a weighted average interest rate of 1.7% . Contractual repayments of the term loan began September 30, 2015 and are due as follows: Year Ended December 31, Principal Repayment (In thousands) 2015 $ 1,875 2016 14,375 2017 25,625 2018 32,500 2019 273,750 $ 348,125 The fair value of outstanding borrowings of the Senior Credit Facility's revolving credit facility and term loan components at September 30, 2015 was approximately $153.7 million and $326.2 million , respectively. These fair values were determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly and are other than active market observable inputs that reflect unadjusted quoted prices for identical assets or liabilities. 2016 Convertible Senior Notes On June 15, 2011, the Company issued $230.0 million aggregate principal amount of its 1.625% Convertible Senior Notes due in 2016 (the “2016 Notes”). The 2016 Notes mature on December 15, 2016, and bear interest at a rate of 1.625% per annum payable semi-annually in arrears on December 15 and June 15 of each year. The portion of the debt proceeds that was classified as equity at the time of the offering was $43.2 million , an equivalent of that amount is being amortized to interest expense using the effective interest method through December 2016. The effective interest rate implicit in the liability component is 5.6% . The 2016 Notes are senior, unsecured obligations of the Company, and are convertible into cash and, if applicable, shares of its common stock based on an initial conversion rate, subject to adjustment of 17.4092 shares per $1,000 principal amount of 2016 Notes (which represents an initial conversion price of approximately $57.44 per share). The Company will satisfy any conversion of the 2016 Notes with cash up to the principal amount of the 2016 Notes pursuant to the net share settlement mechanism set forth in the indenture and, with respect to any excess conversion value, with shares of the Company’s common stock. The 2016 Notes are convertible only in the following circumstances: (1) if the closing sale price of the Company’s common stock exceeds 150% of the conversion price during a period as defined in the indenture; (2) if the average trading price per $1,000 principal amount of the 2016 Notes is less than or equal to 98% of the average conversion value of the 2016 Notes during a period as defined in the indenture; (3) at any time on or after June 15, 2016 ; or (4) if specified corporate transactions occur. The issue price of the 2016 Notes was equal to their face amount, which is also the amount holders are entitled to receive at maturity if the 2016 Notes are not converted. As of March 31, 2015, certain conversion features were triggered due to the announced spin-off of the Company's subsidiary, SeaSpine Holdings Corporation, which allowed the holders to convert all or any of the 2016 Notes subject to certain conditions. The 2016 Notes were convertible through June 10, 2015 and as of the close of the conversion window, note holders provided notice to convert 2,903 notes. During the three-months ended September 30, 2015, the Company paid $2.9 million in cash and issued 8,457 shares to settle the obligation to the note holders that converted. As a result of the spin-off and pursuant to the indenture for the Company's 2016 Notes, the initial conversion price and rate was adjusted effective July 1, 2015. The conversion price on the 2016 Notes has been adjusted to $52.83 per share and the new conversion rate is 18.9287 shares per $1,000 principal amount of 2016 Notes. In connection with the issuance of the 2016 Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of such notes (the “hedge participants”). The initial strike price of the call transaction is approximately $57.44 per share, subject to customary anti-dilution adjustments. The initial strike price of the warrant transaction is approximately $70.05 per share, subject to customary anti-dilution adjustments. Similarly, the strike price of the call transaction has been adjusted to $52.83 per share and the warrant transaction has been adjusted to $64.43 per share. At September 30, 2015 , the carrying amount of the liability component was $216.6 million , the remaining unamortized discount was $10.5 million , and the principal amount outstanding was $227.1 million . The fair value of the 2016 Notes at September 30, 2015 was approximately $272.1 million . At December 31, 2014 , the carrying amount of the liability component was $213.1 million , the remaining unamortized discount was $16.9 million and the principal amount outstanding was $230.0 million . The fair value of the liability of the 2016 Notes was determined using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2. Convertible Note Interest The interest expense components of the Company’s convertible notes are as follows (net of capitalized interest amounts): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 (In thousands) 2016 Notes: Amortization of the discount on the liability component $ 2,142 $ 1,822 $ 5,874 $ 5,256 Cash interest related to the contractual interest coupon 885 853 2,548 2,491 Total $ 3,027 $ 2,675 $ 8,422 $ 7,747

DERIVATIVE INSTRUMENTS

DERIVATIVE INSTRUMENTS	9 Months Ended
	Sep. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE INSTRUMENTS	DERIVATIVE INSTRUMENTS Interest Rate Hedging The Company’s interest rate risk relates to U.S. dollar denominated variable LIBOR interest rate borrowings. On August 10, 2015 the interest rate swap derivative instrument the Company entered into on August 10, 2010 with an effective date of December 31, 2010 expired. The interest rate swap was used to manage the Company's earnings and cash flow exposure to changes in interest rates by converting a portion of its floating-rate debt into fixed-rate debt. The Company did not enter into another interest rate swap derivative instrument. Prior to expiration, the Company designated this derivative instrument as a cash flow hedge. The Company recorded the effective portion of any change in the fair value of a derivative instrument designated as a cash flow hedge as unrealized gains or losses in accumulated other comprehensive income (“AOCI”), net of tax, until the hedged item affected earnings, at which point the effective portion of any gain or loss was reclassified to earnings. If the hedged cash flow does not occur, or if it becomes probable that it will not occur, the Company reclassified the amount of any gain or loss on the related cash flow hedge to interest expense at that time. The Company reclassified $0.2 million of pre-tax losses recorded as net in AOCI related to the interest rate hedge to earnings prior to the date of expiration. Foreign Currency Hedging From time to time the Company enters into foreign currency hedge contracts intended to protect the U.S. dollar value of certain forecasted foreign currency denominated transactions. The Company records the effective portion of any change in the fair value of foreign currency cash flow hedges in AOCI, net of tax, until the hedged item affects earnings. Once the related hedged item affects earnings, the Company reclassifies the effective portion of any related unrealized gain or loss on the foreign currency cash flow hedge to earnings. If the hedged forecasted transaction does not occur, or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. The success of the Company’s hedging program depends, in part, on forecasts of certain activity denominated in euros. The Company may experience unanticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activity during periods of currency volatility. In addition, changes in currency exchange rates related to any unhedged transactions may affect its earnings and cash flows. There were no contracts outstanding as of September 30, 2015 . Counterparty Credit Risk The Company manages its concentration of counterparty credit risk on its derivative instruments by limiting acceptable counterparties to a group of major financial institutions with investment grade credit ratings, and by actively monitoring their credit ratings and outstanding positions on an ongoing basis. Therefore, the Company considers the credit risk of the counterparties to be low. Furthermore, none of the Company’s derivative transactions are subject to collateral or other security arrangements, and none contain provisions that depend upon the Company’s credit ratings from any credit rating agency. Fair Value of Derivative Instruments The Company has classified all of its derivative instruments within Level 2 of the fair value hierarchy because observable inputs are available for substantially the full term of the derivative instruments. The fair value of the foreign currency forward exchange contracts related to inventory purchases is determined by comparing the forward rate as of the period end and the settlement rate specified in each contract. The fair value of the interest rate swaps was developed using a market approach based on publicly available market yield curves and the terms of the related swap. The Company performs ongoing assessments of counterparty credit risk. The following table summarizes the fair value and presentation for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of September 30, 2015 and December 31, 2014 : Fair Value as of Location on Balance Sheet (1) : September 30, 2015 December 31, 2014 (In thousands) Derivatives designated as hedges — Liabilities: Interest rate swap — Accrued expenses and other current liabilities (2) $ — $ 898 Total Derivatives designated as hedges — Liabilities $ — $ 898 (1) The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months. (2) At September 30, 2015 and December 31, 2014 , the notional amount related to the Company’s sole interest rate swap was $0.0 million and $97.5 million , respectively. As of September 30, 2015, the Company reduced the notional amount by the entire remaining $90.0 million as the swap expired. The following presents the effect of derivative instruments designated as cash flow hedges on the accompanying condensed consolidated statements of operations during the three and nine months ended September 30, 2015 and 2014 : Balance in AOCI Beginning of Quarter Amount of Loss Recognized in AOCI- Effective Portion Amount of Loss Reclassified from AOCI into Earnings-Effective Portion Balance in AOCI End of Quarter Location in Statements of Operations (In thousands) Three Months Ended September 30, 2015 Interest rate swap (161 ) — (161 ) — Interest (expense) $ (161 ) $ — $ (161 ) $ — Three Months Ended September 30, 2014 Interest rate swap (1,713 ) (9 ) (433 ) (1,289 ) Interest (expense) $ (1,713 ) $ (9 ) $ (433 ) $ (1,289 ) Balance in AOCI Beginning of Quarter Amount of Loss Recognized in AOCI- Effective Portion Amount of Loss Reclassified from AOCI into Earnings-Effective Portion Balance in AOCI End of Quarter Location in Statements of Operations (In thousands) Nine Months Ended September 30, 2015 Interest rate swap (898 ) (25 ) (923 ) — Interest (expense) $ (898 ) $ (25 ) $ (923 ) $ — Nine Months Ended September 30, 2014 Interest rate swap (2,439 ) (179 ) (1,329 ) (1,289 ) Interest (expense) $ (2,439 ) $ (179 ) $ (1,329 ) $ (1,289 ) The Company recognized no gains or losses resulting from ineffectiveness of cash flow hedges during the nine months ended September 30, 2015 and 2014 .

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION As of September 30, 2015 , the Company had stock options, restricted stock awards, performance stock units, contract stock awards and restricted stock unit awards outstanding under three plans, the 2000 Equity Incentive Plan (the “2000 Plan”), the 2001 Equity Incentive Plan (the “2001 Plan”), and the 2003 Equity Incentive Plan (the “2003 Plan,” and collectively, the “Plans”). Stock options issued under the Plans become exercisable over specified periods, generally within four years from the date of grant for officers, directors, and employees, and generally expire eight years from the grant date for employees, and from eight to ten years for directors and certain executive officers. Restricted stock issued under the Plans vests over specified periods, generally three years after the date of grant. The vesting of performance stock, issued under the Plans, is subject to service and performance conditions. In connection with the separation of SeaSpine on July 1, 2015 and in accordance with the Employee Matters Agreement, the Company made certain adjustments to the exercise price and number of share-based compensation awards with the intention of preserving the intrinsic value of the awards prior to the separation. Stock options issued in 2015 prior to the separation converted to those of the entity where the employee is working post-separation. Stock options issued prior to 2015 converted to both Integra and SeaSpine options such that the holders received stock options in both companies. The exercise price of these outstanding awards was adjusted to preserve the value of the awards immediately prior to the separation. Performance stock, restricted stock, and contract stock were adjusted to provide holders performance stock, restricted stock, and contract stock in the company that employs such employee following the separation. The adjustments to the Company's stock-based compensation awards resulted in an increase in incremental fair value of $4.4 million , of which $3.0 million was recorded in the three months ended September 30, 2015. The remaining $1.4 million will be recognized prospectively over the remaining term of outstanding awards, adjusted, as applicable, for forfeitures. Stock Options As of September 30, 2015 , there were approximately $2.6 million of total unrecognized compensation costs related to unvested stock options, including the additional incremental fair value expense discussed above. These costs are expected to be recognized over a weighted-average period of approximately two years . There were 166,751 stock options granted during the nine months ended September 30, 2015 . Awards of Restricted Stock, Performance Stock and Contract Stock Performance stock, restricted stock and contract stock awards generally have requisite service periods of three years. Performance stock units are subject to graded vesting conditions and the Company expenses their fair value over the requisite service period. The Company expenses the fair value of restricted stock and contract stock awards on a straight-line basis over the vesting period or requisite service period, whichever is shorter. As of September 30, 2015 , there were approximately $18.9 million of total unrecognized compensation costs related to these unvested awards, including the additional incremental fair value expense discussed above. The Company expects to recognize these costs over a weighted-average period of approximately two years . The Company granted 325,411 restricted stock awards/stock units and 139,259 performance shares during the nine months ended September 30, 2015 . The Company has no formal policy related to the repurchase of shares for the purpose of satisfying stock-based compensation obligations. The Company also maintains an Employee Stock Purchase Plan (the “ESPP”), which provides eligible employees with the opportunity to acquire shares of common stock at periodic intervals by means of accumulated payroll deductions. The ESPP is a non-compensatory plan based on its terms.

TREASURY STOCK

TREASURY STOCK	9 Months Ended
	Sep. 30, 2015
Treasury Stock Transactions, Excluding Value of Shares Reissued [Abstract]
TREASURY STOCK	TREASURY STOCK On October 28, 2014, the Board of Directors terminated the October 2012 authorization and authorized up to $75.0 million of its outstanding common stock through December 2016. The Company has not repurchased any of its outstanding shares of common stock during the nine -month periods ended September 30, 2015 and 2014 . As of September 30, 2015 , there remained $75.0 million available for repurchases under this authorization.

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The following table provides a summary of the Company’s effective tax rate: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Reported tax rate 694.6 % 18.0 % 119.7 % 28.4 % The Company’s effective income tax rates for the three and nine months ended September 30, 2015 were 694.6% and 119.7% respectively. The 2015 income tax expense for both periods includes $35.6 million of expense relating to a tax valuation allowance recorded in its continuing operations as a result of the spin-off of the spine business. The Company determined that upon spin-off, the deferred tax assets of the spine business would be unrealizable. Excluding the valuation allowance, the Company's effective income tax rates for the three months ended September 30, 2015 and 2014 were 29.8% and 18.0% , respectively. The primary drivers of the overall tax rate for the three months ended September 30, 2015 were a tax expense of $0.3 million relating to the filing of foreign income tax returns and the settlement of foreign audits. The primary driver of the overall tax rate for the three months ended September 30, 2014 was a benefit of $1.6 million for the release of uncertain tax positions and related interest due to expiration of statute of limitations. Excluding the valuation allowance, the Company's effective income tax rates for the nine months ended September 30, 2015 and 2014 were 33.1% and 28.6% , respectively. The primary driver of the overall tax rate for the nine months ended September 30, 2015 were a tax expense of $0.9 million relating to the filing of Federal and foreign income tax returns. The primary driver of the overall tax rate for the nine months ended September 30, 2014 was a benefit of $1.9 million for the release of uncertain tax positions and related interest due to expiration of statute of limitations. The Company expects its effective income tax rate for the full year to be approximately 87% , driven largely by the tax expense of $35.6 million in its continuing operations, relating to the establishment of a valuation allowance created upon the SeaSpine spin-off. The valuation allowance is due to the deferred tax assets having been impaired by the decision to spin-off the business into a separate entity that, more likely than not, will not be able to realize the value of those deferred tax assets. Excluding the valuation allowance adjustment, the Company expects its effective income tax rate for the full year to be approximately 32.0% , resulting largely from audit settlements, offset with benefits from the domestic manufacturing deduction and the release of uncertain tax positions, as well as the jurisdictional mix of pretax income in U.S.-based operations relative to foreign operations. This estimate could be revised in the future as additional information is presented to the Company.

NET INCOME PER SHARE

NET INCOME PER SHARE	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
NET INCOME PER SHARE	NET INCOME PER SHARE Basic and diluted net income per share was as follows: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 (In thousands, except per share amounts) Basic net income (loss) per share: Net (loss) income from continuing operations $ (31,881 ) $ 8,990 $ (8,129 ) $ 15,890 Net income (loss) from discontinued operations $ — 817 $ (10,370 ) 948 Net (loss) income $ (31,881 ) $ 9,807 $ (18,499 ) $ 16,838 Weighted average common shares outstanding 35,279 32,450 33,682 32,374 Basic net (loss) income per common share from continuing operations $ (0.90 ) $ 0.28 $ (0.24 ) $ 0.49 Basic net income (loss) per common share from discontinued operations — 0.03 (0.31 ) 0.03 Basic net (loss) income per common share $ (0.90 ) $ 0.31 $ (0.55 ) $ 0.52 Diluted net income per share: Net (loss) income from continuing operations $ (31,881 ) $ 8,990 $ (8,129 ) $ 15,890 Net income (loss) from discontinued operations — 817 (10,370 ) 948 Net (loss) income $ (31,881 ) $ 9,807 $ (18,499 ) $ 16,838 Weighted average common shares outstanding — Basic 35,279 32,450 33,682 32,374 Effect of dilutive securities: 2016 Convertible notes — — — — Stock options and restricted stock — 456 — 470 Weighted average common shares for diluted earnings per share 35,279 32,906 33,682 32,844 Diluted net (loss) income per common share from continuing operations $ (0.90 ) $ 0.27 $ (0.24 ) $ 0.48 Diluted net income (loss) per common share from discontinued operations — 0.02 (0.31 ) 0.03 Diluted net (loss) income per common share $ (0.90 ) $ 0.29 $ (0.55 ) $ 0.51 In connection with the separation of SeaSpine on July 1, 2015 and in accordance with the Employee Matters Agreement the Company made certain adjustments to the exercise price and number of share-based compensation awards with the intention of preserving the intrinsic value of the awards prior to the separation. Stock options issued in 2015 prior to the separation converted to those of the entity where the employee is working post-separation. Stock options issued prior to 2015 converted to both Integra and SeaSpine options such that the holders received stock options in both companies. The exercise price of these outstanding awards was adjusted to preserve the value of the awards immediately prior to the separation. Performance stock, restricted stock, and contract stock were adjusted to provide holders performance stock, restricted stock, and contract stock in the company that employs such employee following the separation. The adjustments to the Company's stock-based compensation awards resulted in an increase in incremental fair value of $4.4 million , of which $3.0 million was recorded in the three-months ended September 30, 2015. The remaining $1.4 million will be recognized prospectively over the remaining term of outstanding awards, adjusted, as applicable, for forfeitures. At September 30, 2015 and 2014 , the Company had 1.1 million and 1.4 million of outstanding stock options, respectively. The Company also has warrants outstanding relating to its 2016 Notes at September 30, 2015 and 2014 and the Company's 2016 Notes are convertible to common shares in certain circumstances. See Note 6 - Debt for additional information. Stock options, restricted stock, warrants and the excess conversion value of the 2016 Notes are included in the diluted earnings per share calculation using the treasury stock method, unless the effect of including such items would be anti-dilutive. For the three months ended September 30, 2015 and 2014 , 0.5 million and 0.2 million , respectively, of anti-dilutive stock options and certain other performance awards were excluded from the diluted earnings per share calculation. For the nine months ended September 30, 2015 and 2014 , 0.6 million and 0.2 million , respectively, of anti-dilutive stock options and certain other performance awards were excluded from the diluted earnings per share calculation. The effects of outstanding warrants were anti-dilutive because the strike price of the warrants exceeded the Company’s average stock price for the periods presented. For the three and nine months ended September 30, 2015 , the potential excess conversion value on the 2016 Notes was included in the Company's dilutive share calculation because the average stock price for the three and nine months ended September 30, 2015 exceeded the conversion price. The potential excess conversion value of the 2016 Notes were anti-dilutive because the conversion price exceeded the Company's stock price for the three and nine months ended September 30, 2014 ; therefore, these amounts have been excluded from the diluted earnings per share calculation.

COMPREHENSIVE INCOME (LOSS)

COMPREHENSIVE INCOME (LOSS)	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
COMPREHENSIVE INCOME (LOSS)	COMPREHENSIVE INCOME (LOSS) Comprehensive income (loss) was as follows: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 (In thousands) Net (loss) income $ (31,881 ) $ 8,990 $ (8,129 ) $ 15,890 Foreign currency translation adjustment (393 ) (16,537 ) (17,621 ) (15,952 ) Unrealized currency translation adjustment accelerated upon spin (1,884 ) — (1,884 ) — Change in unrealized gain on derivatives, net of tax 92 241 512 655 Pension liability adjustment, net of tax 751 125 758 52 Comprehensive (loss) income $ (33,315 ) $ (7,181 ) $ (26,364 ) $ 645 Changes in Accumulated Other Comprehensive Loss by component between December 31, 2014 and September 30, 2015 are presented in the table below, net of tax: Gains and (Losses) on Cash Flow Hedges Defined Benefit Pension Items Foreign Currency Items Total (In thousands) Beginning balance $ (512 ) $ (906 ) $ (22,070 ) $ (23,488 ) Other comprehensive income (loss) before reclassifications (14 ) 758 (19,505 ) (18,761 ) Amounts reclassified from accumulated other comprehensive income 526 — — 526 Net current-period other comprehensive income (loss) 512 758 (19,505 ) (18,235 ) Ending balance $ — $ (148 ) $ (41,575 ) $ (41,723 ) The reclassification adjustments out of Accumulated Other Comprehensive Loss during the three and nine months ended September 30, 2015 were as follows: Three Months Ended September 30, 2015 Details about Accumulated Other Comprehensive Income (Loss) Components Amount Reclassified from Accumulated Other Comprehensive Income (Loss) Affected Line Item in the Statement where Net Income (Loss) is Presented (In thousands) Gains and losses on cash flow hedges Interest rate swap $ (161 ) Interest (expense) 69 Tax (expense) or benefit $ (92 ) Net of tax Nine Months Ended September 30, 2015 Details about Accumulated Other Comprehensive Income (Loss) Components Amount Reclassified from Accumulated Other Comprehensive Income (Loss) Affected Line Item in the Statement where Net Income (Loss) is Presented (In thousands) Gains and losses on cash flow hedges Interest rate swap $ (923 ) Interest (expense) 397 Tax (expense) or benefit $ (526 ) Net of tax

SEGMENT AND GEOGRAPHIC INFORMAT

SEGMENT AND GEOGRAPHIC INFORMATION	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
SEGMENT AND GEOGRAPHIC INFORMATION	SEGMENT AND GEOGRAPHIC INFORMATION In the first quarter of 2015, the Company began to disclose three global reportable segments as a result of changes in how the Company internally manages and reports the results of its businesses to its chief operating decision maker. On July 1, 2015, the Company completed the separation of its spine business, which was a reportable segment. See Note 2 - Discontinued Operations for additional information. Following the separation, the Company is disclosing two reportable segments. The two reportable segments and their activities are described below: • The Specialty Surgical Solutions segment includes (i) the Neurosurgery business, which sells a full line of products for neurosurgery and Neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment and (ii) the Instruments business, which sells more than 60,000 instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. • The Orthopedics and Tissue Technologies segment includes such offerings as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts and nerve and tendon repair. The most notable change from the Company's financial statements for the year ended December 31, 2014 included in the Annual Report on Form 10-K is the integration of the former International reportable segment into the segments noted above as well as certain products from the Private Label segment into Orthopedics and Tissue Technologies and Spine. The Spine Private Label products were included in the separation of the spine business. The Corporate and other category includes (i) various legal, finance, information systems, executive, and human resource functions, (ii) brand management, and (iii) share-based compensation costs. Prior to the realignment, costs related to procurement, manufacturing operations and logistics for the Company's entire organization were not allocated to operating segments. In connection with the realignment, a portion of these costs have now been incorporated into the disclosed operating segments. The operating results of the various reportable segments as presented are not comparable to one another because (i) certain operating segments are more dependent than others on corporate functions for unallocated general and administrative and/or operational manufacturing functions, and (ii) the Company does not allocate certain manufacturing costs and general and administrative costs to the operating segment results. Net sales and profit by reportable segment for the three and nine months ended September 30, 2015 and 2014 are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 (In thousands) Segment Net Sales Specialty Surgical Solutions $ 147,085 $ 137,494 $ 433,834 $ 402,210 Orthopedics and Tissue Technologies 79,282 60,029 207,740 175,433 Total revenues $ 226,367 $ 197,523 $ 641,574 $ 577,643 Segment Profit Specialty Surgical Solutions $ 61,017 $ 54,406 $ 183,674 $ 151,694 Orthopedics and Tissue Technologies 20,072 20,812 59,095 59,354 Segment profit 81,089 75,218 242,769 211,048 Amortization (2,942 ) (1,598) (6,418) (4,839) Corporate and other (68,153 ) (56,513 ) (180,772) (167,933 ) Operating income from continuing operations $ 9,994 $ 17,107 $ 55,579 $ 38,276 The Company attributes revenues to geographic areas based on the location of the customer. Total revenue by major geographic area consisted of the following: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 (In thousands) United States $ 178,290 $ 150,867 $ 493,559 $ 433,865 Europe 24,275 22,369 75,046 70,207 Rest of World 23,802 24,287 72,969 73,571 Total Revenues $ 226,367 $ 197,523 $ 641,574 $ 577,643

RETIREMENT BENEFIT PLANS

RETIREMENT BENEFIT PLANS	9 Months Ended
	Sep. 30, 2015
Compensation and Retirement Disclosure [Abstract]
RETIREMENT BENEFIT PLANS	RETIREMENT BENEFIT PLANS Defined Benefit Plans The Company maintains a defined benefit pension plan that covers employees in its manufacturing plant located in Andover, United Kingdom (the “UK Plan”). In March 2011, the Company froze the benefits due to the participants of the UK Plan in their entirety, and in 2015, the Company began the process of investigating the viability of buying-out the UK Plan. The purpose of the buy-out was to substantially reduce the administrative costs of maintaining the UK Plan, indemnify the Company from future claims and transfer all remaining obligations of the UK Plan to a highly-rated independent financial services firm in the UK where it will be maintained and managed. In September 2015, the Company completed the UK Plan buy-out and transferred all of the UK Plan assets to an independent financial services firm and also made cash contributions of approximately $1.8 million during the quarter. The impact to the Company’s condensed consolidated statement of operations for the three and nine months ended September 30, 2015 was to record expenses totaling approximately $5.6 million in selling, general and administrative costs.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES In consideration for certain technology, manufacturing, distribution, and selling rights and licenses granted to the Company, the Company has agreed to pay royalties on sales of certain products that it sells. The royalty payments that the Company made under these agreements were not significant for any of the periods presented. The Company is subject to various claims, lawsuits and proceedings in the ordinary course of the Company's business, including claims by current or former employees, distributors and competitors and with respect to its products and product liability claims, lawsuits and proceedings, some of which have been settled by the Company. In the opinion of management, such claims are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material adverse effect on our financial condition. However, it is possible that the Company's results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies. TEI manufactures a bovine-derived surgical mesh product for Boston Scientific Corporation ("BSC”) and has been named as a defendant in lawsuits under a broad range of products liability theories, many of which have not been served on TEI. Currently, there are approximately fifty active cases against TEI. Pursuant to an indemnification agreement with BSC (i) BSC is managing the litigation; (ii) TEI has in place a products liability insurance policy, of which it must exhaust $3.0 million before BSC’s indemnity begins to cover relevant claims (and of which only a small portion has been utilized to date and against which the insurer has reserved the entire $3.0 million ). Because the thrust of products liability litigation focuses on synthetic surgical mesh products, counsel is filing motions to dismiss on behalf of TEI in many cases. In addition, Integra has certain protections in the merger agreements with TEI which would indemnify it for approximately $30.0 million for the first fifteen months after closing and between $20.0 and $30.0 million for the remainder of the three -year period after closing for losses relating to a variety of matters, including half of certain products liability claims (including those related to the product it manufactures for BSC) not covered by insurance. The Company accrues for loss contingencies when it is deemed probable that a loss has been incurred and that loss is estimable. The amounts accrued are based on the full amount of the estimated loss before considering insurance proceeds, and do not include an estimate for legal fees expected to be incurred in connection with the loss contingency. The Company consistently accrues legal fees expected to be incurred in connection with loss contingencies as those fees are incurred by outside counsel as a period cost.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS Acquisition of the United States rights to certain Tornier N.V Product Portfolios On October 2, 2015, the Company announced that it had completed the acquisition of the United States rights to Tornier's Salto Talaris® and Salto Talaris® XT ankle replacement products and Tornier's FuturaTM silastic toe replacement products for a cash purchase price of approximately $6.0 million . Under the agreement, Integra has acquired the U.S. rights to the Salto Talaris® Total Ankle Prosthesis, Salto Talaris® XT Revision Total Ankle Prosthesis, Futura™ Primus Flexible Great Toe system, Futura™ Classic Flexible Great Toe system, and Futura™ Lesser Metatarsal Phalangeal system. The agreement also includes an option to purchase, in the future, the rights to the Salto Talaris®, Salto Talaris® XT, Salto Mobile, and Futura™ silastic toe replacement products outside the United States.

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Recently Issued Accounting Standards	Recently Issued Accounting Standards In April 2014, the FASB issued amendments to guidance for reporting discontinued operations and disposals of components of an entity. The amended guidance requires that a disposal representing a strategic shift that has (or will have) a major effect on an entity’s financial results or a business activity classified as held for sale should be reported as discontinued operations. The amendments also expand the disclosure requirements for discontinued operations and add new disclosures for individually significant dispositions that do not qualify as discontinued operations. The amendments are effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2014 (early adoption is permitted only for disposals that have not been previously reported). The new guidance is effective for Integra prospectively for all disposals (or classifications as held for sale) of components of an entity that occur after January 1, 2015. The spin-off of the spine business by the Company on July 1, 2015 met the definition of a discontinued operation under the new guidance and, as a result, the Company reflected the provisions of the new guidance in its third quarter 2015 results. In May 2014, the FASB issued Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) . The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should 1) identify the contract(s) with a customer, 2) identify the performance obligations in the contract, 3) determine the transaction price, 4) allocate the transaction price to the performance obligations in the contract, and 5) recognize revenue when (or as) the entity satisfies a performance obligation. In July 2015, the FASB deferred for one year the effective date of the new revenue standard, but early adoption will be permitted. The new standard will be effective for the Company on January 1, 2018. The Company is in the process of evaluating the impact of this standard on its financial statements. In June 2014, the FASB issued Update No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (Topic 718). The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718 as it relates to awards with performance conditions that affect vesting to account for such awards. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. This update is effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period, and early adoption is permitted. The implementation of the amended guidance is not expected to have a material impact on the consolidated financial position or results of operations. In August 2014, the FASB issued Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern . The amendment requires management to evaluate, for each annual and interim reporting period, whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date the financial statements are issued or are available to be issued. If substantial doubt is raised, additional disclosures around management’s plan to alleviate these doubts are required. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2016. The implementation of the amended guidance is not expected to have an impact on current disclosures in the financial statements. In April 2015, the FASB issued Update No. 2015-03, Simplifying the Presentation of Debt Issuance Costs . The amendment requires that all costs incurred to issue debt be presented in the balance sheet as a direct deduction from the carrying value of the debt. The new standard is limited to the presentation of debt issuance costs and does not affect the recognition or measurement of debt issuance costs. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2015. The implementation of the amended guidance is not expected to have a material impact on the consolidated results of operations and will result in a reclassification of the debt issuance costs from other long-term assets to long-term debt when adopted. In August 2015, the FASB issued Update No. 2015-15, Interest - Imputation of Interest . The amendment requires entities to present debt issuance costs related to a recognized debt liability as a direct deduction from the carrying amount of that debt liability. The guidance in ASU No. 2015-03 does not address presentation or subsequent measurement of debt issuance costs related to line-of-credit arrangements. Given the absence of authoritative guidance within ASU No. 2015-03 for debt issuance costs related to line-of-credit arrangements, the SEC staff would not object to an entity's deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2015. The implementation of the amended guidance is not expected to have a material impact on the consolidated financial position or results of operations. In September 2015, the FASB issued Update No. 2015-16, Simplifying the Accounting for Measurement-Period Adjustments . The amendment requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. This update also requires an entity to present separately in the income statement or disclose in the notes, the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2015. The new standard must be applied prospectively to adjustments to provisional amounts that occur after the effective date. Early application is permitted for financial statements that have not been issued. The implementation of the amended guidance is not expected to have a material impact on the consolidated results of operations or disclosures in the financial statements. There are no other recently issued accounting standards that are expected to have a material effect on the financial position, results of operations or cash flows.

DISCONTINUED OPERATIONS (Tables

DISCONTINUED OPERATIONS (Tables)	9 Months Ended
	Sep. 30, 2015
Discontinued Operations and Disposal Groups [Abstract]
Balance Sheet and Income Statement of Disposal Group	The following table presents Integra's spine business assets and liabilities presented as discontinued operations as of December 31, 2014: December 31, 2014 (in thousands) Assets: Cash $ 260 Accounts receivable 21,504 Inventory 47,981 Other current assets 30,040 Current assets of discontinued operations 99,785 Property, plant, and equipment, net 16,360 Intangible assets, net 46,891 Other assets 10,483 Non-current assets of discontinued operations 73,734 Total assets of discontinued operations $ 173,519 Liabilities: Accounts payable $ 5,193 Accrued compensation 6,300 Accrued expenses and other current liabilities 2,287 Current liabilities of discontinued operations 13,780 Other liabilities 2,631 Long-term liabilities of discontinued operations 2,631 Total liabilities of discontinued operations $ 16,411 The following table presents Integra's spine business assets and liabilities removed from the condensed consolidated balance sheet as of July 1, 2015: July 1, 2015 (in thousands) Assets: Cash $ 46,848 Accounts receivable 21,273 Inventory 49,380 Other current assets 16,262 Current assets of discontinued operations 133,763 Property, plant, and equipment, net 21,079 Intangible assets, net 42,837 Other assets 4,449 Non-current assets of discontinued operations 68,365 Total assets of discontinued operations $ 202,128 Liabilities: Accounts payable $ 7,065 Accrued compensation 5,960 Accrued expenses and other current liabilities 3,350 Current liabilities of discontinued operations 16,375 Deferred tax liabilities 13,329 Other liabilities 2,500 Long-term liabilities of discontinued operations 15,829 Total liabilities of discontinued operations $ 32,204 The following table summarizes results from discontinued operations of SeaSpine included in the condensed consolidated statement of operations: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 (in thousands) (in thousands) Total revenue $ — $ 33,606 $ 65,775 $ 102,658 Costs and expenses — 32,986 80,618 102,077 Operating income (loss) — 620 (14,843 ) 581 Other income (expense), net — (34 ) (766 ) (61 ) Income (loss) from discontinued operations before tax — 586 (15,609 ) 520 Provision (benefit) for income taxes — (231 ) (5,239 ) (428 ) Net income (loss) from discontinued operations $ — $ 817 $ (10,370 ) $ 948

BUSINESS ACQUISITIONS (Tables)

BUSINESS ACQUISITIONS (Tables)	9 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Schedule of Purchase Price Allocation	The following summarizes the preliminary allocation of the purchase price as of September 30, 2015 based on the fair value of the assets acquired and liabilities assumed: Preliminary Purchase Price Allocation (Dollars in thousands) Cash $ 1,241 Accounts receivable, net 9,011 Inventory 23,223 Income tax receivable 5,135 Other current assets 2,270 Property, plant, and equipment 2,027 Intangible assets: Wtd. Avg. Life: Developed Technology 167,400 14 -16 Contractual Relationships 51,345 11 -14 Leasehold Interest 69 Goodwill 148,935 Total assets acquired 410,656 Accrued expenses and other liabilities 9,732 Deferred tax liabilities 88,565 Net assets acquired $ 312,359 The following summarizes the final allocation of the purchase price as of September 30, 2015 based on the fair value of the assets acquired and liabilities assumed: Final Purchase Price Allocation (Dollars in thousands) Inventory $ 4,800 Property, plant, and equipment 1,246 Intangible assets: Wtd. Avg. Life: Technology product rights 20,590 8 - 14 Years In-process research and development 190 Indefinite Goodwill 732 Net assets acquired $ 27,558 The following summarizes the final allocation of the purchase price as of September 30, 2015 based on the fair value of the assets acquired and liabilities assumed: Final Purchase Price Allocation (Dollars in thousands) Inventory deposit $ 4,000 Fixed assets 438 Intangible assets: Wtd. Avg. Life Technology product rights 239,800 3 - 20 Years Other 400 Less than 1 year Deferred tax assets - long term 12 Goodwill 105,331 Total assets acquired 349,981 Contingent supply liability 5,891 Other 731 Deferred tax liabilities - long term 87,464 Net assets acquired $ 255,895 The following summarizes the final allocation of the purchase price as of September 30, 2015 based on the fair value of the assets acquired and liabilities assumed: Final Purchase Price Allocation (Dollars in thousands) Cash $ 2,195 Inventory 3,155 Prepaid expenses 620 Property, plant, and equipment 3,675 Other current assets 5,025 Intangible assets: Wtd. Avg. Life: Trade name 11,990 20 Years Technology 4,580 15 - 16 Years Customer relationships 18,130 12 - 16 Years Goodwill 16,607 Total assets acquired 65,977 Accounts payable and other liabilities 5,910 Net assets acquired $ 60,067
Schedule of Contingent Consideration	A reconciliation of the opening balances to the closing balances of these Level 3 measurements is as follows (in thousands): Location in Statement of Operations Balance as of January 1, 2015 $ 22,008 Loss from increase in fair value of contingent consideration liabilities 359 Selling, general and administrative Fair value at September 30, 2015 $ 22,367
Pro Forma Information	As a result, these pro forma results do not necessarily represent results that would have occurred if the acquisition had taken place on the basis assumed above, nor are they indicative of the results of future combined operations. Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 (In thousands, except per share amounts) (In thousands, except per share amounts) Total revenue $ 229,402 $ 223,837 $ 677,740 $ 656,584 Net (loss) income $ (31,697 ) $ 10,160 $ (5,930 ) $ 20,251 Net (loss) income per share: Basic $ (0.90 ) $ 0.31 $ (0.18 ) $ 0.63

INVENTORIES (Tables)

INVENTORIES (Tables)	9 Months Ended
	Sep. 30, 2015
Inventory, Net [Abstract]
Schedule of Inventory, Net	Inventories, net consisted of the following: September 30, 2015 December 31, 2014 (In thousands) Finished goods $ 130,626 $ 120,477 Work in process 46,861 38,938 Raw materials 36,391 29,718 $ 213,878 $ 189,133

GOODWILL AND OTHER INTANGIBLE26

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Changes In Carrying Amount Of Goodwill	Changes in the carrying amount of goodwill for the nine months ended September 30, 2015 were as follows: Specialty Surgical Solutions Orthopedics and Tissue Technologies Total (In thousands) Goodwill at December 31, 2014 $ 281,829 $ 81,650 $ 363,479 MicroFrance working capital and purchase price adjustments (1,069 ) — (1,069 ) Metasurg working capital and purchase price adjustment — 263 263 TEI Acquisition — 148,935 148,935 Foreign currency translation (4,363 ) (1,518 ) (5,881 ) Balance, September 30, 2015 $ 276,397 $ 229,330 $ 505,727
Components of Company's Identifiable Intangible Assets	The components of the Company’s identifiable intangible assets were as follows: September 30, 2015 Weighted Average Life Cost Accumulated Amortization Net (Dollars in thousands) Completed technology 17 years $ 480,991 $ (61,030 ) $ 419,961 Customer relationships 12 years 153,344 (66,729 ) 86,615 Trademarks/brand names (2) 30 years 91,288 (15,830 ) 75,458 Supplier relationships 27 years 34,721 (11,879 ) 22,842 All other (1) 4 years 2,721 (1,177 ) 1,544 $ 763,065 $ (156,645 ) $ 606,420 December 31, 2014 Weighted Average Life Cost Accumulated Amortization Net (Dollars in thousands) Completed technology 18 years $ 314,664 $ (46,339 ) $ 268,325 Customer relationships 13 years 105,201 (63,689 ) 41,512 Trademarks/brand names 34 years 44,220 (15,455 ) 28,765 Trademarks/brand names (2) Indefinite 48,484 — 48,484 Supplier relationships 27 years 34,721 (10,809 ) 23,912 All other (1) 4 years 2,910 (1,340 ) 1,570 $ 550,200 $ (137,632 ) $ 412,568 (1) At September 30, 2015 and December 31, 2014 , all other included in-process research and development ("IPR&D") of $1.4 million in both periods, which was indefinite-lived. (2) In August 2015, the Company reevaluated the Miltex, CUSA, Luxtec, and Omni-Tract trade names and determined that they are no longer indefinite-lived intangible assets. The Company assigned remaining useful lives ranging from 20 to 30 years , consistent with other trademarks/brand names, and began amortization.

DEBT (Tables)

DEBT (Tables)	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Schedule of Maturities of Long-term Debt	At September 30, 2015 there was $348.1 million outstanding under the term loan component of the Senior Credit Facility at a weighted average interest rate of 1.7% . Contractual repayments of the term loan began September 30, 2015 and are due as follows: Year Ended December 31, Principal Repayment (In thousands) 2015 $ 1,875 2016 14,375 2017 25,625 2018 32,500 2019 273,750 $ 348,125
Components of Interest Expense	The interest expense components of the Company’s convertible notes are as follows (net of capitalized interest amounts): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 (In thousands) 2016 Notes: Amortization of the discount on the liability component $ 2,142 $ 1,822 $ 5,874 $ 5,256 Cash interest related to the contractual interest coupon 885 853 2,548 2,491 Total $ 3,027 $ 2,675 $ 8,422 $ 7,747

DERIVATIVE INSTRUMENTS (Tables)

DERIVATIVE INSTRUMENTS (Tables)	9 Months Ended
	Sep. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Fair Value In Balance Sheet For Derivatives Designated As Hedging Instruments	The following table summarizes the fair value and presentation for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of September 30, 2015 and December 31, 2014 : Fair Value as of Location on Balance Sheet (1) : September 30, 2015 December 31, 2014 (In thousands) Derivatives designated as hedges — Liabilities: Interest rate swap — Accrued expenses and other current liabilities (2) $ — $ 898 Total Derivatives designated as hedges — Liabilities $ — $ 898 (1) The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months. (2) At September 30, 2015 and December 31, 2014 , the notional amount related to the Company’s sole interest rate swap was $0.0 million and $97.5 million , respectively. As of September 30, 2015, the Company reduced the notional amount by the entire remaining $90.0 million
Effect of Derivative Instruments Designated as Cash Flow Hedges on Statements of Operations	The following presents the effect of derivative instruments designated as cash flow hedges on the accompanying condensed consolidated statements of operations during the three and nine months ended September 30, 2015 and 2014 : Balance in AOCI Beginning of Quarter Amount of Loss Recognized in AOCI- Effective Portion Amount of Loss Reclassified from AOCI into Earnings-Effective Portion Balance in AOCI End of Quarter Location in Statements of Operations (In thousands) Three Months Ended September 30, 2015 Interest rate swap (161 ) — (161 ) — Interest (expense) $ (161 ) $ — $ (161 ) $ — Three Months Ended September 30, 2014 Interest rate swap (1,713 ) (9 ) (433 ) (1,289 ) Interest (expense) $ (1,713 ) $ (9 ) $ (433 ) $ (1,289 ) Balance in AOCI Beginning of Quarter Amount of Loss Recognized in AOCI- Effective Portion Amount of Loss Reclassified from AOCI into Earnings-Effective Portion Balance in AOCI End of Quarter Location in Statements of Operations (In thousands) Nine Months Ended September 30, 2015 Interest rate swap (898 ) (25 ) (923 ) — Interest (expense) $ (898 ) $ (25 ) $ (923 ) $ — Nine Months Ended September 30, 2014 Interest rate swap (2,439 ) (179 ) (1,329 ) (1,289 ) Interest (expense) $ (2,439 ) $ (179 ) $ (1,329 ) $ (1,289 )

INCOME TAXES (Tables)

INCOME TAXES (Tables)	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Schedule of effective income tax rate reconciliation	The following table provides a summary of the Company’s effective tax rate: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Reported tax rate 694.6 % 18.0 % 119.7 % 28.4 %

NET INCOME PER SHARE (Tables)

NET INCOME PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Basic and Diluted Net Income Per Share	Basic and diluted net income per share was as follows: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 (In thousands, except per share amounts) Basic net income (loss) per share: Net (loss) income from continuing operations $ (31,881 ) $ 8,990 $ (8,129 ) $ 15,890 Net income (loss) from discontinued operations $ — 817 $ (10,370 ) 948 Net (loss) income $ (31,881 ) $ 9,807 $ (18,499 ) $ 16,838 Weighted average common shares outstanding 35,279 32,450 33,682 32,374 Basic net (loss) income per common share from continuing operations $ (0.90 ) $ 0.28 $ (0.24 ) $ 0.49 Basic net income (loss) per common share from discontinued operations — 0.03 (0.31 ) 0.03 Basic net (loss) income per common share $ (0.90 ) $ 0.31 $ (0.55 ) $ 0.52 Diluted net income per share: Net (loss) income from continuing operations $ (31,881 ) $ 8,990 $ (8,129 ) $ 15,890 Net income (loss) from discontinued operations — 817 (10,370 ) 948 Net (loss) income $ (31,881 ) $ 9,807 $ (18,499 ) $ 16,838 Weighted average common shares outstanding — Basic 35,279 32,450 33,682 32,374 Effect of dilutive securities: 2016 Convertible notes — — — — Stock options and restricted stock — 456 — 470 Weighted average common shares for diluted earnings per share 35,279 32,906 33,682 32,844 Diluted net (loss) income per common share from continuing operations $ (0.90 ) $ 0.27 $ (0.24 ) $ 0.48 Diluted net income (loss) per common share from discontinued operations — 0.02 (0.31 ) 0.03 Diluted net (loss) income per common share $ (0.90 ) $ 0.29 $ (0.55 ) $ 0.51

COMPREHENSIVE INCOME (LOSS) (Ta

COMPREHENSIVE INCOME (LOSS) (Tables)	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Schedule of Comprehensive (Loss) Income	Comprehensive income (loss) was as follows: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 (In thousands) Net (loss) income $ (31,881 ) $ 8,990 $ (8,129 ) $ 15,890 Foreign currency translation adjustment (393 ) (16,537 ) (17,621 ) (15,952 ) Unrealized currency translation adjustment accelerated upon spin (1,884 ) — (1,884 ) — Change in unrealized gain on derivatives, net of tax 92 241 512 655 Pension liability adjustment, net of tax 751 125 758 52 Comprehensive (loss) income $ (33,315 ) $ (7,181 ) $ (26,364 ) $ 645
Schedule of Changes in Accumulated Other Comprehensive Income by Component	Changes in Accumulated Other Comprehensive Loss by component between December 31, 2014 and September 30, 2015 are presented in the table below, net of tax: Gains and (Losses) on Cash Flow Hedges Defined Benefit Pension Items Foreign Currency Items Total (In thousands) Beginning balance $ (512 ) $ (906 ) $ (22,070 ) $ (23,488 ) Other comprehensive income (loss) before reclassifications (14 ) 758 (19,505 ) (18,761 ) Amounts reclassified from accumulated other comprehensive income 526 — — 526 Net current-period other comprehensive income (loss) 512 758 (19,505 ) (18,235 ) Ending balance $ — $ (148 ) $ (41,575 ) $ (41,723 )
Reclassification out of Accumulated Other Comprehensive Income (Loss)	The reclassification adjustments out of Accumulated Other Comprehensive Loss during the three and nine months ended September 30, 2015 were as follows: Three Months Ended September 30, 2015 Details about Accumulated Other Comprehensive Income (Loss) Components Amount Reclassified from Accumulated Other Comprehensive Income (Loss) Affected Line Item in the Statement where Net Income (Loss) is Presented (In thousands) Gains and losses on cash flow hedges Interest rate swap $ (161 ) Interest (expense) 69 Tax (expense) or benefit $ (92 ) Net of tax Nine Months Ended September 30, 2015 Details about Accumulated Other Comprehensive Income (Loss) Components Amount Reclassified from Accumulated Other Comprehensive Income (Loss) Affected Line Item in the Statement where Net Income (Loss) is Presented (In thousands) Gains and losses on cash flow hedges Interest rate swap $ (923 ) Interest (expense) 397 Tax (expense) or benefit $ (526 ) Net of tax

SEGMENT AND GEOGRAPHIC INFORM32

SEGMENT AND GEOGRAPHIC INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Total Revenue By Major Geographic Area	Net sales and profit by reportable segment for the three and nine months ended September 30, 2015 and 2014 are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 (In thousands) Segment Net Sales Specialty Surgical Solutions $ 147,085 $ 137,494 $ 433,834 $ 402,210 Orthopedics and Tissue Technologies 79,282 60,029 207,740 175,433 Total revenues $ 226,367 $ 197,523 $ 641,574 $ 577,643 Segment Profit Specialty Surgical Solutions $ 61,017 $ 54,406 $ 183,674 $ 151,694 Orthopedics and Tissue Technologies 20,072 20,812 59,095 59,354 Segment profit 81,089 75,218 242,769 211,048 Amortization (2,942 ) (1,598) (6,418) (4,839) Corporate and other (68,153 ) (56,513 ) (180,772) (167,933 ) Operating income from continuing operations $ 9,994 $ 17,107 $ 55,579 $ 38,276 The Company attributes revenues to geographic areas based on the location of the customer. Total revenue by major geographic area consisted of the following: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 (In thousands) United States $ 178,290 $ 150,867 $ 493,559 $ 433,865 Europe 24,275 22,369 75,046 70,207 Rest of World 23,802 24,287 72,969 73,571 Total Revenues $ 226,367 $ 197,523 $ 641,574 $ 577,643

BASIS OF PRESENTATION - Narrati

BASIS OF PRESENTATION - Narrative (Details) - Spinoff - SeaSpine Inc.	Jul. 02, 2015shares
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Distribution of spinoff shares	100.00%
Shares of Integra for share of SeaSpine	3

DISCONTINUED OPERATIONS - Sched

DISCONTINUED OPERATIONS - Schedule of Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net income (loss) from discontinued operations	$ 0	$ 817	$ (10,370)	$ 948
SeaSpine Inc. | Spinoff
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenue	0	33,606	65,775	102,658
Costs and expenses	0	32,986	80,618	102,077
Operating income (loss)	0	620	(14,843)	581
Other income (expense), net	0	(34)	(766)	(61)
Income (loss) from discontinued operations before tax	0	586	(15,609)	520
Provision (benefit) for income taxes	0	(231)	(5,239)	(428)
Net income (loss) from discontinued operations	$ 0	$ 817	$ (10,370)	$ 948

DISCONTINUED OPERATIONS - Dispo

DISCONTINUED OPERATIONS - Disposal Group Balance Sheet (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Jul. 02, 2015	Dec. 31, 2014	Oct. 29, 2014
Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]
Current assets of discontinued operations	$ 0		$ 99,785
Disposal Group, Including Discontinued Operation, Assets, Noncurrent [Abstract]
Non-current assets of discontinued operations	0		73,734
Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]
Current liabilities of discontinued operations	0		13,780
Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent [Abstract]
Long-term liabilities of discontinued operations	$ 0		2,631
SeaSpine Inc. | Spinoff
Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]
Cash		$ 46,848	260	$ 47,000
Accounts receivable		21,273	21,504
Inventory		49,380	47,981
Other current assets		16,262	30,040
Current assets of discontinued operations		133,763	99,785
Disposal Group, Including Discontinued Operation, Assets, Noncurrent [Abstract]
Property, plant, and equipment, net		21,079	16,360
Intangible assets, net		42,837	46,891
Other assets		4,449	10,483
Non-current assets of discontinued operations		68,365	73,734
Total assets of discontinued operations		202,128	173,519
Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]
Accounts payable		7,065	5,193
Accrued compensation		5,960	6,300
Accrued expenses and other current liabilities		3,350	2,287
Current liabilities of discontinued operations		16,375	13,780
Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent [Abstract]
Deferred tax liabilities		13,329
Other liabilities		2,500	2,631
Long-term liabilities of discontinued operations		15,829	2,631
Total liabilities of discontinued operations		$ 32,204	$ 16,411

DISCONTINUED OPERATIONS - Narra

DISCONTINUED OPERATIONS - Narrative (Details)	Jul. 02, 2015USD ($)directorshares	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Dec. 31, 2014USD ($)	Oct. 29, 2014USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income (loss) from discontinued operations (net of tax expense, (benefit))		$ 0	$ 817,000	$ (10,370,000)	$ 948,000
SeaSpine Inc. | Spinoff
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Distribution of spinoff shares	100.00%
Shares of Integra for share of SeaSpine | shares	3
Cash	$ 46,848,000					$ 260,000	$ 47,000,000
Discontinued Operations, Gain (Loss) on Distribution of Interest in Discontinued Operation, Net of Tax	$ 0
Income (loss) from discontinued operations (net of tax expense, (benefit))		0	817,000	(10,370,000)	948,000
SeaSpine Inc. | Spinoff | Director
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of shared board members | director	3
SeaSpine Inc. | Spinoff | Investor
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued Operations, Gain (Loss) on Distribution of Interest in Discontinued Operation, Net of Tax	$ 0
Supply Commitment | SeaSpine Inc.
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Period of continuing involvement after spinoff	3 years
Revenue of SeaSpine		1,900,000	1,400,000	7,500,000	4,200,000
Expenses of SeaSpine		1,100,000	$ 600,000	$ 2,400,000	$ 1,900,000
Information Technology and Administrative Support | SeaSpine Inc.
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue of SeaSpine		$ 1,800,000

BUSINESS ACQUISITIONS - Narrati

BUSINESS ACQUISITIONS - Narrative (Details) $ in Thousands	Jul. 17, 2015USD ($)acquisition	Dec. 05, 2014USD ($)	Oct. 27, 2014USD ($)	Jan. 15, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)
Business Acquisition [Line Items]
Business acquired | acquisition	2
Cash used in business acquisition, net of cash acquired							$ 308,256	$ 235,000
Impairment of intangible assets							0	600
TEI Biosciences Inc and TEI Medical Inc.
Business Acquisition [Line Items]
Consideration for acquisition	$ 312,400
Cash used in business acquisition, net of cash acquired	312,400
Cash	1,200				$ 1,241		1,241
Revenue of acquired company since acquisition					13,200		13,200
Net assets acquired					312,359		312,359
TEI Biosciences Inc.
Business Acquisition [Line Items]
Consideration for acquisition	210,400
TEI Medical Inc.
Business Acquisition [Line Items]
Consideration for acquisition	$ 102,000
Metasurg
Business Acquisition [Line Items]
Consideration for acquisition		$ 27,600
Revenue of acquired company since acquisition					1,800		5,100
Adjustment of consideration for acquisition		400					400
Payments for acquisition		26,500
Contingent consideration acquisition		700
Business acquisition, additional cash consideration payable upon completion of milestones		$ 38,500
Fair value inputs, discount rate		19.90%
Net assets acquired					27,558		27,558
Working capital and purchase price adjustment							263
Medtronic MicroFrance
Business Acquisition [Line Items]
Cash					2,195		2,195
Revenue of acquired company since acquisition					6,700		18,800
Adjustment of consideration for acquisition			$ (1,500)				1,500
Payments for acquisition			60,100
Adjustment to goodwill			$ 800
Net assets acquired					60,067		60,067
Working capital and purchase price adjustment							(1,069)
Confluent Surgical, Inc.
Business Acquisition [Line Items]
Revenue of acquired company since acquisition					20,600	$ 17,700	57,200	$ 50,100
Contingent consideration acquisition				$ 20,900
Business acquisition, additional cash consideration payable upon completion of milestones				$ 30,000
Fair value inputs, discount rate				2.20%
Net assets acquired				$ 255,895	$ 255,895		255,895
Payments to acquire business interest				231,000
Payments for transitional supply agreements from acquisition				$ 4,000
Contingent liability extension period				2 years
Consideration liability, number of required days for extension				180 days
Contingent liability, period of consideration arrangement				5 years
Contingent liability, period of transitional supply price increases				3 years
Impairment of intangible assets							$ 600
Fair value input, probability of event				95.00%
Incremental increase in contingent liability				$ 300
Incremental decrease in contingent liability				400
Confluent Surgical, Inc. | Potential Cash Consideration Fair Value
Business Acquisition [Line Items]
Business acquisition, additional cash consideration payable upon completion of milestones				25,000
Confluent Surgical, Inc. | Cash Consideration Two
Business Acquisition [Line Items]
Business acquisition, additional cash consideration payable upon completion of milestones				$ 5,000
Deferred Tax Liability | Confluent Surgical, Inc.
Business Acquisition [Line Items]
Working capital and purchase price adjustment						$ 12,400

BUSINESS ACQUISITIONS - Schedul

BUSINESS ACQUISITIONS - Schedule of Purchase Price Allocation (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Jul. 17, 2015	Dec. 31, 2014	Jan. 15, 2014
Business Acquisition [Line Items]
Goodwill	$ 505,727		$ 363,479
TEI Biosciences Inc and TEI Medical Inc.
Business Acquisition [Line Items]
Cash	1,241	$ 1,200
Accounts receivable, net	9,011
Inventory	23,223
Income tax receivable	5,135
Other current assets	2,270
Fixed assets	2,027
Goodwill	148,935
Total assets acquired	410,656
Deferred tax liabilities - long term	88,565
Accounts payable and other liabilities	9,732
Net assets acquired	312,359
TEI Biosciences Inc and TEI Medical Inc. | Developed Technology Rights
Business Acquisition [Line Items]
Finite intangible assets	$ 167,400
TEI Biosciences Inc and TEI Medical Inc. | Developed Technology Rights | Minimum
Business Acquisition [Line Items]
Weighted average useful life	14 years
TEI Biosciences Inc and TEI Medical Inc. | Developed Technology Rights | Maximum
Business Acquisition [Line Items]
Weighted average useful life	16 years
TEI Biosciences Inc and TEI Medical Inc. | Customer relationships
Business Acquisition [Line Items]
Finite intangible assets	$ 51,345
TEI Biosciences Inc and TEI Medical Inc. | Customer relationships | Minimum
Business Acquisition [Line Items]
Weighted average useful life	11 years
TEI Biosciences Inc and TEI Medical Inc. | Customer relationships | Maximum
Business Acquisition [Line Items]
Weighted average useful life	14 years
TEI Biosciences Inc and TEI Medical Inc. | Leasehold Interest
Business Acquisition [Line Items]
Finite intangible assets	$ 69
Metasurg
Business Acquisition [Line Items]
Inventory	4,800
Fixed assets	1,246
Goodwill	732
Net assets acquired	27,558
Metasurg | In Process Research and Development
Business Acquisition [Line Items]
Indefinite intangible assets	190
Metasurg | Technology-Based Intangible Assets
Business Acquisition [Line Items]
Finite intangible assets	$ 20,590
Metasurg | Technology-Based Intangible Assets | Minimum
Business Acquisition [Line Items]
Weighted average useful life	8 years
Metasurg | Technology-Based Intangible Assets | Maximum
Business Acquisition [Line Items]
Weighted average useful life	14 years
Medtronic MicroFrance
Business Acquisition [Line Items]
Cash	$ 2,195
Inventory	3,155
Inventory deposit	620
Other current assets	5,025
Fixed assets	3,675
Goodwill	16,607
Total assets acquired	65,977
Accounts payable and other liabilities	5,910
Net assets acquired	60,067
Medtronic MicroFrance | Trade Names
Business Acquisition [Line Items]
Finite intangible assets	$ 11,990
Medtronic MicroFrance | Trade Names | Maximum
Business Acquisition [Line Items]
Weighted average useful life	20 years
Medtronic MicroFrance | Technology-Based Intangible Assets
Business Acquisition [Line Items]
Finite intangible assets	$ 4,580
Medtronic MicroFrance | Technology-Based Intangible Assets | Minimum
Business Acquisition [Line Items]
Weighted average useful life	15 years
Medtronic MicroFrance | Technology-Based Intangible Assets | Maximum
Business Acquisition [Line Items]
Weighted average useful life	16 years
Medtronic MicroFrance | Customer relationships
Business Acquisition [Line Items]
Finite intangible assets	$ 18,130
Medtronic MicroFrance | Customer relationships | Minimum
Business Acquisition [Line Items]
Weighted average useful life	12 years
Medtronic MicroFrance | Customer relationships | Maximum
Business Acquisition [Line Items]
Weighted average useful life	16 years
Confluent Surgical, Inc.
Business Acquisition [Line Items]
Inventory deposit	$ 4,000
Fixed assets	438
Deferred tax assets - long term	12
Goodwill	105,331
Total assets acquired	349,981
Contingent supply liability	5,891
Other	731
Deferred tax liabilities - long term	87,464
Net assets acquired	$ 255,895			$ 255,895
Confluent Surgical, Inc. | Technology-Based Intangible Assets | Minimum
Business Acquisition [Line Items]
Weighted average useful life	3 years
Confluent Surgical, Inc. | Technology-Based Intangible Assets | Maximum
Business Acquisition [Line Items]
Weighted average useful life	20 years
Confluent Surgical, Inc. | Developed Technology Rights
Business Acquisition [Line Items]
Finite intangible assets	$ 239,800
Confluent Surgical, Inc. | Other Intangible Assets
Business Acquisition [Line Items]
Finite intangible assets	$ 400
Confluent Surgical, Inc. | Other Intangible Assets | Maximum
Business Acquisition [Line Items]
Weighted average useful life	1 year

BUSINESS ACQUISITIONS - Sched39

BUSINESS ACQUISITIONS - Schedule of Contingent Consideration (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Business Acquisition, Contingent Consideration [Roll Forward]
Loss from increase in fair value of contingent consideration liabilities	$ 359	$ (878)
Level 3 | Potential Cash Consideration Fair Value
Business Acquisition, Contingent Consideration [Roll Forward]
Balance as of January 1, 2015	22,008
Fair value at September 30, 2015	22,367
Level 3 | Selling, General and Administrative Expenses | Potential Cash Consideration Fair Value
Business Acquisition, Contingent Consideration [Roll Forward]
Loss from increase in fair value of contingent consideration liabilities	$ 359

BUSINESS ACQUISITIONS - Pro For

BUSINESS ACQUISITIONS - Pro Forma Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Business Acquisition [Line Items]
Total revenue	$ 229,402	$ 223,837	$ 677,740	$ 656,584
Net (loss) income	$ (31,697)	$ 10,160	$ (5,930)	$ 20,251
Basic (in dollars per share)	$ (0.90)	$ 0.31	$ (0.18)	$ 0.63

INVENTORIES (Inventory, Net) (D

INVENTORIES (Inventory, Net) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Inventory, Net [Abstract]
Finished goods	$ 130,626	$ 120,477
Work-in process	46,861	38,938
Raw materials	36,391	29,718
Inventories, net	$ 213,878	$ 189,133

GOODWILL AND OTHER INTANGIBLE42

GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Goodwill [Roll Forward]
Goodwill at December 31, 2014	$ 363,479
Foreign currency translation	(5,881)
Balance, September 30, 2015	505,727
Specialty Surgical Solutions
Goodwill [Roll Forward]
Goodwill at December 31, 2014	281,829
Foreign currency translation	(4,363)
Balance, September 30, 2015	276,397
Orthopedics and Tissue Technologies
Goodwill [Roll Forward]
Goodwill at December 31, 2014	81,650
Foreign currency translation	(1,518)
Balance, September 30, 2015	229,330
Medtronic MicroFrance
Goodwill [Roll Forward]
Working capital and purchase price adjustment	(1,069)
Balance, September 30, 2015	16,607
Medtronic MicroFrance | Specialty Surgical Solutions
Goodwill [Roll Forward]
Working capital and purchase price adjustment	(1,069)
Medtronic MicroFrance | Orthopedics and Tissue Technologies
Goodwill [Roll Forward]
Working capital and purchase price adjustment	0
Metasurg
Goodwill [Roll Forward]
Working capital and purchase price adjustment	263
Balance, September 30, 2015	732
Metasurg | Specialty Surgical Solutions
Goodwill [Roll Forward]
Working capital and purchase price adjustment	0
Metasurg | Orthopedics and Tissue Technologies
Goodwill [Roll Forward]
Working capital and purchase price adjustment	263
TEI Biosciences Inc and TEI Medical Inc.
Goodwill [Roll Forward]
Goodwill, Acquired During Period	148,935
Balance, September 30, 2015	148,935
TEI Biosciences Inc and TEI Medical Inc. | Specialty Surgical Solutions
Goodwill [Roll Forward]
Goodwill, Acquired During Period	0
TEI Biosciences Inc and TEI Medical Inc. | Orthopedics and Tissue Technologies
Goodwill [Roll Forward]
Goodwill, Acquired During Period	$ 148,935

GOODWILL AND OTHER INTANGIBLE43

GOODWILL AND OTHER INTANGIBLE ASSETS - Components of Company's Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended	12 Months Ended
	Aug. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Acquired Finite-Lived Intangible Assets [Line Items]
Cost Of Definite And Indefinite Lived Intangible Assets Gross Excluding Goodwill		$ 763,065	$ 550,200
Finite-Lived Intangible Assets, Accumulated Amortization		(156,645)	(137,632)
Definite And Indefinite Lived Intangible Assets Net Excluding Goodwill		606,420	412,568
Completed Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Cost Of Definite And Indefinite Lived Intangible Assets Gross Excluding Goodwill		480,991	314,664
Finite-Lived Intangible Assets, Accumulated Amortization		(61,030)	(46,339)
Definite And Indefinite Lived Intangible Assets Net Excluding Goodwill		$ 419,961	$ 268,325
Finite-Lived Intangible Asset, Useful Life		17 years	18 years
Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Cost Of Definite And Indefinite Lived Intangible Assets Gross Excluding Goodwill		$ 153,344	$ 105,201
Finite-Lived Intangible Assets, Accumulated Amortization		(66,729)	(63,689)
Definite And Indefinite Lived Intangible Assets Net Excluding Goodwill		$ 86,615	$ 41,512
Finite-Lived Intangible Asset, Useful Life		12 years	13 years
Trademarks Brand Names
Acquired Finite-Lived Intangible Assets [Line Items]
Cost Of Definite And Indefinite Lived Intangible Assets Gross Excluding Goodwill		$ 91,288	$ 44,220
Finite-Lived Intangible Assets, Accumulated Amortization		(15,830)	(15,455)
Definite And Indefinite Lived Intangible Assets Net Excluding Goodwill		$ 75,458	$ 28,765
Finite-Lived Intangible Asset, Useful Life		30 years	34 years
Trademarks Brand Names Indefinite
Acquired Finite-Lived Intangible Assets [Line Items]
Cost Of Definite And Indefinite Lived Intangible Assets Gross Excluding Goodwill			$ 48,484
Finite-Lived Intangible Assets, Accumulated Amortization			0
Definite And Indefinite Lived Intangible Assets Net Excluding Goodwill			48,484
Supplier Relation Ships
Acquired Finite-Lived Intangible Assets [Line Items]
Cost Of Definite And Indefinite Lived Intangible Assets Gross Excluding Goodwill		$ 34,721	34,721
Finite-Lived Intangible Assets, Accumulated Amortization		(11,879)	(10,809)
Definite And Indefinite Lived Intangible Assets Net Excluding Goodwill		$ 22,842	$ 23,912
Finite-Lived Intangible Asset, Useful Life		27 years	27 years
All Other
Acquired Finite-Lived Intangible Assets [Line Items]
Cost Of Definite And Indefinite Lived Intangible Assets Gross Excluding Goodwill		$ 2,721	$ 2,910
Finite-Lived Intangible Assets, Accumulated Amortization		(1,177)	(1,340)
Definite And Indefinite Lived Intangible Assets Net Excluding Goodwill		$ 1,544	$ 1,570
Finite-Lived Intangible Asset, Useful Life		4 years	4 years
In Process Research and Development
Acquired Finite-Lived Intangible Assets [Line Items]
Other Indefinite-lived Intangible Assets		$ 1,400	$ 1,400
Minimum | Trademarks Brand Names
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	20 years
Maximum | Trademarks Brand Names
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	30 years

GOODWILL AND OTHER INTANGIBLE44

GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) $ in Thousands	3 Months Ended	9 Months Ended		12 Months Ended
	Mar. 31, 2015Segment	Sep. 30, 2015USD ($)Segment	Sep. 30, 2014USD ($)	Dec. 31, 2014Segment
Goodwill [Line Items]
Number of reportable segments | Segment	3	2		5
Impairment of intangible assets		$ 0	$ 600
Annual amortization expense expected to approximate in 2015		36,000
Annual amortization expense expected to approximate in 2016		40,500
Annual amortization expense expected to approximate in 2017		39,700
Annual amortization expense expected to approximate in 2018		39,600
Annual amortization expense expected to approximate in 2019		39,500
Confluent Surgical, Inc.
Goodwill [Line Items]
Impairment of intangible assets		$ 600

DEBT -Narrative (Details)

DEBT -Narrative (Details)	Aug. 28, 2015USD ($)	Jul. 02, 2015$ / shares	Jul. 02, 2014USD ($)	Jun. 15, 2011USD ($)$ / shares	Sep. 30, 2015USD ($)shares	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Jun. 10, 2015convertible_debt_instrument	Dec. 31, 2014USD ($)
Debt Instrument [Line Items]
Amortization of debt issuance costs						$ 1,645,000	$ 2,060,000
Carrying amount of liability					$ 216,604,000	216,604,000			$ 213,121,000
Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit facility outstanding					$ 165,000,000	$ 165,000,000			$ 266,900,000
Weighted average interest rate on debt					1.70%	1.70%			1.70%
Available borrowings under senior secured revolving credit facility					$ 586,900,000	$ 586,900,000
Line of credit facility, fair value of amount outstanding					153,700,000	153,700,000
Term Loan
Debt Instrument [Line Items]
Line of credit facility outstanding					$ 348,100,000	$ 348,100,000
Weighted average interest rate on debt					1.70%	1.70%
Long-term debt, fair value					$ 326,200,000	$ 326,200,000
Convertible Debt
Debt Instrument [Line Items]
Principal amount outstanding				$ 230,000,000	227,097,000	227,097,000			$ 230,000,000
Interest rate on debt				1.625%
Portion of the debt proceeds that was classified as equity at the time of the offering				$ 43,200,000
Effective interest rate implicit in the liability component				5.60%
Common stock based on initial conversion rate ratio (in shares)		18.9287		17.4092
Principal amount to be considered for conversion purpose				$ 1,000
Initial conversion price, per share | $ / shares		$ 52.83		$ 57.44
Maximum selling price of company's common stock				150.00%
Principal amount of notes per average trading price				$ 1,000
Maximum average conversion value of the Notes				98.00%
Number debt instruments pending conversion | convertible_debt_instrument								2,903
Repayments of Debt					$ 2,900,000
Stock Issued During Period, Shares, Conversion of Convertible Securities | shares					8,457
Strike price of the call transaction (in dollars per share) | $ / shares		52.83		$ 57.44
Strike price of warrant transactions (in dollars per share) | $ / shares		$ 64.43		$ 70.05
Carrying amount of liability					$ 216,600,000	216,600,000			213,100,000
Unamortized discount					10,500,000	10,500,000			$ 16,900,000
Fair value of outstanding borrowings					$ 272,100,000	$ 272,100,000
August 2015 Amendment
Debt Instrument [Line Items]
Senior credit facility, maximum borrowing capacity	$ 1,100,000,000
Additional commitments	200,000,000
Cash balance threshold above which excess amount is not subject to any restriction of use or investment	$ 40,000,000
August 2015 Amendment | Minimum
Debt Instrument [Line Items]
Line of credit, commitment fee percentage	0.15%
August 2015 Amendment | Maximum
Debt Instrument [Line Items]
Line of credit, commitment fee percentage	0.30%
August 2015 Amendment | Standby Letters of Credit
Debt Instrument [Line Items]
Senior credit facility, maximum borrowing capacity	$ 60,000,000
August 2015 Amendment | Revolving Credit Facility
Debt Instrument [Line Items]
Senior credit facility, maximum borrowing capacity	750,000,000
August 2015 Amendment | Swingline Loan
Debt Instrument [Line Items]
Senior credit facility, maximum borrowing capacity	$ 60,000,000
August 2015 Amendment | Federal Funds
Debt Instrument [Line Items]
Interest rates available to the Company at its option	0.50%
August 2015 Amendment | (LIBOR)
Debt Instrument [Line Items]
Interest rates available to the Company at its option	1.00%
August 2015 Amendment | Eurodollar | Minimum
Debt Instrument [Line Items]
Interest rates available to the Company at its option	1.00%
August 2015 Amendment | Eurodollar | Maximum
Debt Instrument [Line Items]
Interest rates available to the Company at its option	1.75%
August 2015 Amendment | Term Loan
Debt Instrument [Line Items]
Senior credit facility, maximum borrowing capacity	$ 350,000,000
Proceeds from lines of credit	$ 200,000,000
July 2014 Amendment
Debt Instrument [Line Items]
Proceeds from lines of credit			$ 422,000,000
Deferred finance costs, gross			3,200,000
Amortization of debt issuance costs			300,000
July 2014 Amendment | Revolving Credit Facility
Debt Instrument [Line Items]
Proceeds from lines of credit			272,000,000
July 2014 Amendment | Term Loan
Debt Instrument [Line Items]
Proceeds from lines of credit			$ 150,000,000

DEBT -5 year payout table (Deta

DEBT -5 year payout table (Details) - Term Loan $ in Thousands	Sep. 30, 2015USD ($)
Line of Credit Facility [Line Items]
2,015	$ 1,875
2,016	14,375
2,017	25,625
2,018	32,500
2,019	273,750
Total repayments	$ 348,125

DEBT - Components of Interest E

DEBT - Components of Interest Expense (Detail) - 2016 Convertible Senior Notes - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Debt Instrument [Line Items]
Amortization of the discount on the liability component	$ 2,142	$ 1,822	$ 5,874	$ 5,256
Cash interest related to the contractual interest coupon	885	853	2,548	2,491
Total	$ 3,027	$ 2,675	$ 8,422	$ 7,747

DERIVATIVE INSTRUMENTS - Narrat

DERIVATIVE INSTRUMENTS - Narrative (Detail)	9 Months Ended
	Sep. 30, 2015USD ($)contract	Sep. 30, 2014USD ($)
Derivative [Line Items]
Interest rate swap expiration date	August 10, 2015
Gain (loss) on hedging ineffectiveness	$ 0	$ 0
Interest Rate Swap
Derivative [Line Items]
Pretax losses expected to be reclassified from AOCI in next 12 months	$ 200,000
Foreign Exchange Contract
Derivative [Line Items]
Derivative contracts | contract	0

DERIVATIVE INSTRUMENTS - Summar

DERIVATIVE INSTRUMENTS - Summary of Fair Value in Balance Sheet for Derivatives Designated Hedging Instruments (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Line Items]
Fair value of derivative liabilities	$ 0	$ 898
Interest Rate Swap
Derivative Instruments and Hedging Activities Disclosure [Line Items]
Notional amount derivative instruments	0	97,500
Reduction in notional amount of interest rate derivatives in next twelve months	90,000
Interest Rate Swap | Accrued expenses and other current liabilities
Derivative Instruments and Hedging Activities Disclosure [Line Items]
Fair value of derivative liabilities	$ 0	$ 898

DERIVATIVE INSTRUMENTS - Effect

DERIVATIVE INSTRUMENTS - Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Derivative Instruments, Gain (Loss) [Line Items]
Balance in AOCI Beginning of Period	$ (161)	$ (1,713)	$ (898)	$ (2,439)
Amount of Loss Recognized in AOCI- Effective Portion	0	(9)	(25)	(179)
Amount of Loss Reclassified from AOCI into Earnings-Effective Portion	(161)	(433)	(923)	(1,329)
Balance in AOCI End of Period	0	(1,289)	0	(1,289)
Interest Expense | Interest Rate Swap
Derivative Instruments, Gain (Loss) [Line Items]
Balance in AOCI Beginning of Period	(161)	(1,713)	(898)	(2,439)
Amount of Loss Recognized in AOCI- Effective Portion	0	(9)	(25)	(179)
Amount of Loss Reclassified from AOCI into Earnings-Effective Portion	(161)	(433)	(923)	(1,329)
Balance in AOCI End of Period	$ 0	$ (1,289)	$ 0	$ (1,289)

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Detail) - USD ($) $ in Millions	Jul. 02, 2015	Sep. 30, 2015	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period, net of forfeitures			166,751
Requisite service periods of awards, in years			3 years
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options exercisable, vesting period, in years			4 years
Total unrecognized compensation costs		$ 2.6	$ 2.6
Weighted-average period for cost recognition, in years			2 years
Restricted stock awards/stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options exercisable, vesting period, in years			3 years
Total unrecognized compensation costs		18.9	$ 18.9
Weighted-average period for cost recognition, in years			2 years
Awards granted during period			325,411
Performance shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted during period			139,259
Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period, in years			8 years
Directors and certain executive officers | Minimum | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period, in years			8 years
Directors and certain executive officers | Maximum | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period, in years			10 years
SeaSpine Inc. | Spinoff
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incremental increase in stock based award expense after spinoff	$ 4.4
Allocated Share-based Compensation Expense		3
Total unrecognized compensation costs		$ 1.4	$ 1.4

TREASURY STOCK (Additional Info

TREASURY STOCK (Additional Information) (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Oct. 28, 2014
Accelerated Share Repurchases [Line Items]
Stock repurchased during period, shares	0	0
Amount available for share repurchase under this latest authorization	$ 75,000,000
October 2012 Authorization
Accelerated Share Repurchases [Line Items]
Stock repurchase program, authorized amount			$ 75,000,000

INCOME TAXES - Narrative (Detai

INCOME TAXES - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2015
Income Tax Contingency [Line Items]
Reported tax rate	694.60%	18.00%	119.70%	28.40%
Tax rate, excluding valuation allowance	29.80%	18.00%	33.10%	28.60%
Change in tax expense due to filing with tax authorities	$ 0.3		$ 0.9
Benefit in tax due to lapse of statue of limitations		$ 1.6		$ 1.9
SeaSpine Inc. | Spinoff
Income Tax Contingency [Line Items]
Increase in deferred tax valuation	$ 35.6		$ 35.6
Forecast
Income Tax Contingency [Line Items]
Reported tax rate					87.00%
Tax rate, excluding valuation allowance					32.00%

INCOME TAXES - Summary of Effec

INCOME TAXES - Summary of Effective Tax Rate (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Tax Disclosure [Abstract]
Reported tax rate	694.60%	18.00%	119.70%	28.40%

NET INCOME PER SHARE - Narrativ

NET INCOME PER SHARE - Narrative (Detail) - USD ($) shares in Millions, $ in Millions	Jul. 02, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock options, shares outstanding (in shares)		1.1	1.4	1.1	1.4
Stock Compensation Plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from computation as their effect would be anti-dilutive		0.5	0.2	0.6	0.2
SeaSpine Inc. | Spinoff
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Incremental increase in stock based award expense after spinoff	$ 4.4
Allocated Share-based Compensation Expense		$ 3
Total unrecognized compensation costs		$ 1.4		$ 1.4

NET INCOME PER SHARE - Basic an

NET INCOME PER SHARE - Basic and Diluted Net Income Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Basic net income (loss) per share:
Net (loss) income from continuing operations	$ (31,881)	$ 8,990	$ (8,129)	$ 15,890
Net income (loss) from discontinued operations	0	817	(10,370)	948
Net (loss) income	$ (31,881)	$ 9,807	$ (18,499)	$ 16,838
Weighted average common shares outstanding (in shares)	35,279	32,450	33,682	32,374
Basic net income (loss) per common share from continuing operations (in dollars per share)	$ (0.90)	$ 0.28	$ (0.24)	$ 0.49
Basic net income (loss) per common share from discontinued operations (in dollars per share)	0	0.03	(0.31)	0.03
Basic net income (loss) per common share (in dollars per share)	$ (0.90)	$ 0.31	$ (0.55)	$ 0.52
Diluted net income per share:
Net (loss) income from continuing operations	$ (31,881)	$ 8,990	$ (8,129)	$ 15,890
Net income (loss) from discontinued operations	0	817	(10,370)	948
Net (loss) income	$ (31,881)	$ 9,807	$ (18,499)	$ 16,838
Weighted average common shares outstanding (in shares)	35,279	32,450	33,682	32,374
Effect of dilutive securities:
2016 Convertible notes (in shares)	0	0	0	0
Stock options and restricted stock (in shares)	0	456	0	470
Weighted average common shares for diluted earnings per share (in shares)	35,279	32,906	33,682	32,844
Diluted net income (loss) per common share from continuing operations (in dollars per share)	$ (0.90)	$ 0.27	$ (0.24)	$ 0.48
Diluted net income (loss) per common share from discontinued operations (in dollars per share)	0	0.02	(0.31)	0.03
Diluted net income (loss) per common share (in dollars per share)	$ (0.90)	$ 0.29	$ (0.55)	$ 0.51

COMPREHENSIVE INCOME (LOSS) - S

COMPREHENSIVE INCOME (LOSS) - Schedule of Comprehensive Loss Income (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Equity [Abstract]
Net (loss) income from continuing operations	$ (31,881)	$ 8,990	$ (8,129)	$ 15,890
Foreign currency translation adjustment	(393)	(16,537)	(17,621)	(15,952)
Unrealized currency translation adjustment accelerated upon spin	(1,884)	0	(1,884)	0
Change in unrealized gain on derivatives, net of tax	92	241	512	655
Pension liability adjustment, net of tax	751	125	758	52
Comprehensive (loss) income	$ (33,315)	$ (7,181)	$ (26,364)	$ 645

COMPREHENSIVE INCOME (LOSS) (Sc

COMPREHENSIVE INCOME (LOSS) (Schedule of Changes in Accumulated Other Comprehensive Income by Component (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	$ 704,322
Other comprehensive income (loss) before reclassifications	(18,761)
Amounts reclassified from accumulated other comprehensive income	526
Net current-period other comprehensive income (loss)	(18,235)
Ending balance	730,100
Gains and Losses on Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(512)
Other comprehensive income (loss) before reclassifications	(14)
Amounts reclassified from accumulated other comprehensive income	526
Net current-period other comprehensive income (loss)	512
Ending balance	0
Defined Benefit Pension Items
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(906)
Other comprehensive income (loss) before reclassifications	758
Amounts reclassified from accumulated other comprehensive income	0
Net current-period other comprehensive income (loss)	758
Ending balance	(148)
Foreign Currency Items
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(22,070)
Other comprehensive income (loss) before reclassifications	(19,505)
Amounts reclassified from accumulated other comprehensive income	0
Net current-period other comprehensive income (loss)	(19,505)
Ending balance	(41,575)
AOCI attributable to Integra
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(23,488)
Ending balance	$ (41,723)

COMPREHENSIVE INCOME (LOSS) (Re

COMPREHENSIVE INCOME (LOSS) (Reclassification Adjustment from AOCI) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest (expense)	$ (6,464)	$ (5,912)	$ (17,404)	$ (16,436)
Tax (expense) or benefit	(37,243)	(1,967)	(49,289)	(6,294)
Net (loss) income	(31,881)	$ 9,807	(18,499)	$ 16,838
Reclassification out of Accumulated Other Comprehensive Income | Gains and Losses on Cash Flow Hedges
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Tax (expense) or benefit	69		397
Net (loss) income	(92)		(526)
Reclassification out of Accumulated Other Comprehensive Income | Gains and Losses on Cash Flow Hedges | Interest Rate Swap
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest (expense)	$ (161)		$ (923)

SEGMENT AND GEOGRAPHIC INFORM60

SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Detail) product in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2015Segment	Sep. 30, 2015Segmentproduct	Dec. 31, 2014Segment
Segment Reporting [Abstract]
Number of reportable segments | Segment	3	2	5
Specialty Surgical Solutions
Segment Reporting Information [Line Items]
Number of products offered		60

SEGMENT AND GEOGRAPHIC INFORM61

SEGMENT AND GEOGRAPHIC INFORMATION - Net Sales and Profit by Reportable Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting Information [Line Items]
Revenues	$ 226,367	$ 197,523	$ 641,574	$ 577,643
Operating income	9,994	17,107	55,579	38,276
Intangible asset amortization	(2,942)	(1,598)	(6,418)	(4,839)
Operating Segments
Segment Reporting Information [Line Items]
Operating income	81,089	75,218	242,769	211,048
Operating Segments | Specialty Surgical Solutions
Segment Reporting Information [Line Items]
Revenues	147,085	137,494	433,834	402,210
Operating income	61,017	54,406	183,674	151,694
Operating Segments | Orthopedics and Tissue Technologies
Segment Reporting Information [Line Items]
Revenues	79,282	60,029	207,740	175,433
Operating income	20,072	20,812	59,095	59,354
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Operating income	$ (68,153)	$ (56,513)	$ (180,772)	$ (167,933)

SEGMENT AND GEOGRAPHIC INFORM62

SEGMENT AND GEOGRAPHIC INFORMATION - Total Revenue by Major Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting Information [Line Items]
Revenues	$ 226,367	$ 197,523	$ 641,574	$ 577,643
United States
Segment Reporting Information [Line Items]
Revenues	178,290	150,867	493,559	433,865
Europe
Segment Reporting Information [Line Items]
Revenues	24,275	22,369	75,046	70,207
Rest of World
Segment Reporting Information [Line Items]
Revenues	$ 23,802	$ 24,287	$ 72,969	$ 73,571

RETIREMENT BENEFIT PLANS - Narr

RETIREMENT BENEFIT PLANS - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015
Compensation and Retirement Disclosure [Abstract]
Contributions to plan	$ 1.8
Expense recognized by benefit plan	$ 5.6	$ 5.6

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Narrative (Details) - TEI Biosciences Inc and TEI Medical Inc. $ in Millions	Jul. 17, 2015USD ($)case
Loss Contingencies [Line Items]
Number of active cases | case	50
Indemnification policy in place	$ 3
Indemnification period - up to fifteen months after close
Loss Contingencies [Line Items]
Period of indemnification	15 months
Maximum indemnification from acquisition	$ 30
Indemnification period - up to 3 years after close
Loss Contingencies [Line Items]
Period of indemnification	3 years
Minimum indemnification from acquisition	$ 20
Maximum indemnification from acquisition	30
Third Party Insurer
Loss Contingencies [Line Items]
Indemnification policy in place	$ 3

SUBSEQUENT EVENTS - Narrative (

SUBSEQUENT EVENTS - Narrative (Details) $ in Millions	Oct. 02, 2015USD ($)
Distribution Rights | Subsequent Event
Subsequent Event [Line Items]
Payments to distribution rights	$ 6